Евразийские клинические рекомендации по профилактике и лечению сердечно-сосудистых заболеваний у больных с ожирением (2022)

Вход
Регистрация
Помощь

Выбрать БД

Журналы и статьиСоздатель/АффиляцияЭнциклопедия MeSH

Простой поискРасширенный поискИстория поисков

Главная / Результаты поиска

СтатьяЕВРАЗ КАРД ЖУР. 2022; № 3: 6–56. DOI:10.38109/2225-1685-2022-3-6-56

Евразийские клинические рекомендации по профилактике и лечению сердечно-сосудистых заболеваний у больных с ожирением (2022)

Отказ от ответственности. Рекомендации ЕАК отражают точку зрения ЕАК и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее, Рекомендации ЕАК никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.

Глобальный план действий по профилактике неинфекционных заболеваний и борьбе с ними на 2013-2020 гг. ВОЗ, Женева, Швейцария; 2013:107с. WHO.URL: http://www.who.int/nmh/events/ncd_action_plan/en/#.http://www.who.int/nmh/events/ncd_action_plan/en/#

Шальнова С.А., Деев А.Д. Масса тела у мужчин и женщин (результаты обследования российской, национальной, представительной выборки населения) Кардиоваскулярная терапия и профилактика. 2008;7(6):60-3.

Шальнова С.А., ДеевА.Д., Баланова Ю.А., и др. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциации в России. Кардиоваскулярная терапия и профилактика, 2017;16(4):4-10. https://doi.org/10.15829/1728-8800-2017-4-4-10.
DOI: 10.15829/1728-8800-2017-4-4-10

Баланова Ю.А., Шальнова С.А., Деев А.Д., Имаева А.Э., Концевая А.В., Муромцева Г.А., Капустина А.В., Евстифеева С.Е., Драпкина О.В. Ожирение в российской популяции — распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;(6):123-130. https://doi.org/10.15829/1560-4071-2018-6-123-130.
DOI: 10.15829/1560-4071-2018-6-123-130

Misra A, Jayawardena R, Anoop S. Obesity in South Asia: Phenotype, Morbidities, and Mitigation. Curr Obes Rep. 2019;8(1):43-52. https://doi.org/10.1007/s13679-019-0328-0.
DOI: 10.1007/s13679-019-0328-0

Cheng L, Yan W, Zhu L, et al. Comparative analysis of IDF, ATPIII and CDS in the diagnosis of metabolic syndrome among adult inhabitants in Jiangxi Province, China. PLoS One. 2017;12(12):e0189046. https://doi.org/10.1371/journal.pone.0189046.
DOI: 10.1371/journal.pone.0189046

Nishida C, Barba C, Cavalli-Sforza T, et al. Appropriate bodymass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. https://doi.org/10.1016/S0140-6736(03)15268-3.
DOI: 10.1016/S0140-6736(03)15268-3

Pan W-H, Yeh W-T. How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations. Asia Pac J Clin Nutr. 2008. https://doi.org/10.6133/apjcn.2008.17.3.02.
DOI: 10.6133/apjcn.2008.17.3.02

Nam GE, Park HS. Perspective on Diagnostic Criteria for Obesity and Abdominal Obesity in Korean Adults. J Obes Metab Syndr. 2018;27(3):134-142. https://doi.org/10.7570/jomes.2018.27.3.134.
DOI: 10.7570/jomes.2018.27.3.134

Zeng Q, He Y, Dong S, et al. Optimal cut-off values of BMI, waist circumference and waist:height ratio for defining obesity in Chinese adults. Br J Nutr. 2014;112(10):1735-1744. https://doi.org/10.1017/S0007114514002657.
DOI: 10.1017/S0007114514002657

Jih J, Mukherjea A, Vittinghoff E, et al. Using appropriate body mass index cut points for overweight and obesity among Asian Americans. Prev Med (Baltim). 2014;65:1-6. https://doi.org/10.1016/j.ypmed.2014.04.010.
DOI: 10.1016/j.ypmed.2014.04.010

Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring). 2020 Jul; 28(7):1195-1199. https://doi.org/10.1002/oby.22831.
DOI: 10.1002/oby.22831

Ekelund, U et al. Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition Study (EPIC) American Journal of Clinical Nutrition. Am J Clin Nutr. 2015 Mar; 101(3):613-621. https://doi.org/10.3945/ajcn.114.100065.
DOI: 10.3945/ajcn.114.100065

Blüher M. O. Metabolically Healthy Obesity. Endocrine Reviews, June 2020; 41(3):1-16. https://doi.org/10.1210/endrev/bnaa004.
DOI: 10.1210/endrev/bnaa004

Caleyachetty R, Thomas GN, Toulis KA, et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol. 2017;70(12):1429-1437. https://doi.org/10.1016/j.jacc.2017.07.763.
DOI: 10.1016/j.jacc.2017.07.763

Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a metaanalysis of prospective cohort studies. Int J Cardiol. 2013;168(5):4761-4768. https://doi.org/10.1016/j.ijcard.2013.07.230.
DOI: 10.1016/j.ijcard.2013.07.230

Zheng R, Zhou D, Zhu Y. The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis. J Epidemiol Community Health. 2016;70(10):1024-1031. https://doi.org/10.1136/jech-2015-206948.
DOI: 10.1136/jech-2015-206948

Moussa O, Arhi C, Ziprin P, Darzi A, Khan O, Purkayastha S. Fate of the metabolically healthy obese-is this term a misnomer? A study from the Clinical Practice Research Datalink. Int J Obes (Lond). 2019;43(5):1093-1101. https://doi.org/10.1038/s41366-018-0096-z.
DOI: 10.1038/s41366-018-0096-z

Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med. 2013;159(11):758-769. https://doi.org/10.7326/0003-4819-159-11-201312030-00008.
DOI: 10.7326/0003-4819-159-11-201312030-00008

Frank L.J. Visseren, Francois Mach, Yvo M. Smulders, David Carballo, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42:3227-3337. https://doi.org/10.1093/eurheartj/ehab484.
DOI: 10.1093/eurheartj/ehab484

Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 1991;266:231-236. PMID: 1829117

Lambert E, Sari CI, Dawood T, Nguyen J, McGrane M, Eikelis N, Chopra R, Wong C, Chatzivlastou K, Head G, Straznicky N, Esler M, Schlaich M, Lambert G. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults.Hypertension. 2010;56:351-358. https://doi.org/10.1161/hypertensionaha.110.155663.
DOI: 10.1161/hypertensionaha.110.155663

Железнова Е.А., Жернакова Ю.В., Погорелова О.А. и др. Состояние сосудистой стенки и его связь с периваскулярной жировой тканью и другими жировыми депо у пациентов молодого возраста с абдоминальным ожирением. Системные гипертензии. 2019;16(4):80-86https://syst-hypertension.ru/2075-082X/article/view/33559https://syst-hypertension.ru/2075-082X/article/view/33559

Bell JA, Hamer M, Sabia S, Singh-Manoux A, Batty GD, Kivimaki M. The natural course of healthy obesity over 20 years. J Am Coll Cardiol 2015;65:101-102. https://doi.org/10.1016/j.jacc.2014.09.077.
DOI: 10.1016/j.jacc.2014.09.077

Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16(1):6-31. https://doi.org/10.26442/2075082X.2019.1.190179.
DOI: 10.26442/2075082X.2019.1.190179

SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439-2454. https://doi.org/10.1093/eurheartj/ehab309.
DOI: 10.1093/eurheartj/ehab309

SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42:2455-2467. https://doi.org/10.1093/eurheartj/ehab312.
DOI: 10.1093/eurheartj/ehab312

Ожирение у взрослых. Клинические рекомендации Минздрава России, 2020.

World Health Organization. Obesity: preventing and managing the global epidemic. 1997, Geneva: WHO.

Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009 Mar 28;373(9669):1083-96. https://doi.org/10.1016/S0140-6736(09)60318-4. Epub 2009 Mar 18. PMID: 19299006; PMCID: PMC2662372..
DOI: 10.1016/S0140-6736(09)60318-4. Epub 2009 Mar 18

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998 Sep;6 Suppl 2:51S-209S. Erratum in: Obes Res 1998 Nov;6(6):464. PMID: 9813653.

Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:I-XII, 1-253. PMID: 11234459.

Garvey WT, Garber AJ, Mechanick JI, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20(9):977-989. https://doi.org/10.4158/ep14280.ps.
DOI: 10.4158/ep14280.ps

Tsai AG, Wadden TA. In the clinic: obesity. Ann Intern Med. 2013 Sep 3;159(5):ITC3-1-ITC3-15; quiz ITC3-16. https://doi.org/10.7326/0003-4819-159-5-201309030-01003. PMID: 24026335..
DOI: 10.7326/0003-4819-159-5-201309030-01003

Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427. https://doi.org/10.1056/nejm199908053410607.
DOI: 10.1056/nejm199908053410607

Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014. JAMA 2016; 315:2292. https://doi.org/10.1001/jama.2016.6361.
DOI: 10.1001/jama.2016.6361

Van Pelt RE, Gavin KM, Kohrt WM. Regulation of Body Composition and Bioenergetics by Estrogens. Endocrinol Metab Clin North Am 2015;44:663. https://doi.org/10.1016/j.ecl.2015.05.011.
DOI: 10.1016/j.ecl.2015.05.011

Kohrt WM, Wierman ME. Preventing Fat Gain by Blocking Follicle-Stimulating Hormone. N Engl J Med 2017;377:293. https://doi.org/10.1056/nejmcibr1704542.
DOI: 10.1056/nejmcibr1704542

Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of WHO/IDF Consultation. 2006

Pearce E. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes. 2012;19:408-13. https://doi.org/10.1097/med.0b013e328355cd6c.
DOI: 10.1097/med.0b013e328355cd6c

Daniel E, Newell-Price J. Cushing’s syndrome. Medicine. 2017;45(8):475-9.

Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrin Metab. 2010;95:3614-7. https://doi.org/10.1210/jc.2010-1245.
DOI: 10.1210/jc.2010-1245

Rotondi M, Magri F, Chiovato L. Thyroid and obesity: not a one-way interaction. J Clin Endocrin Metab. 2011;96:344-6. https://doi.org/10.1210/jc.2010-2515.
DOI: 10.1210/jc.2010-2515

Laurberg P, Knudsen N, Andersen S, et al. Thyroid function and obesity. Eur Thyroid J. 2012;1:159-67. https://doi.org/10.1159/000342994.
DOI: 10.1159/000342994

Duntas L, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013;23:646-53. https://doi.org/10.1089/thy.2011.0499.
DOI: 10.1089/thy.2011.0499

Boscaro M, Arnaldi G. Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3121-31. https://doi.org/10.1210/jc.2009-0612.
DOI: 10.1210/jc.2009-0612

Auriemma R. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab. 2018;13(2):99-106. https://doi.org/10.1080/17446651.2018.1434412.
DOI: 10.1080/17446651.2018.1434412

Dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity. 2011;19:800-5. https://doi.org/10.1038/oby.2010.150.
DOI: 10.1038/oby.2010.150

Lohman, T.G., Roche, A.F. and Martorell, R. (1988) Anthropometric standardization reference manual. Human Kinetics Books, Chicago.

Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res. 2003 Oct;11(10):1223-31. https://doi.org/10.1038/oby.2003.168. PMID: 14569048..
DOI: 10.1038/oby.2003.168

Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, Allison TG, Batsis JA, Sert-Kuniyoshi FH, Lopez-Jimenez F. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond). 2008;32:959-966. https://doi.org/10.1038/ijo.2008.11.
DOI: 10.1038/ijo.2008.11

Pack QR, Rodriguez-Escudero JP, Thomas RJ, Squires RW, Johnson L, Somers VK, Lopez-Jimenez F. Diagnostic performance of weight loss to predict body fatness improvement in cardiac rehabilitation patients. J Cardiopulm Rehabil Prev. 2013;33:68-76. https://doi.org/10.1097/HCR.0b013e31827fe7e3.
DOI: 10.1097/HCR.0b013e31827fe7e3

Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond). 2010;34:791-799. https://doi.org/10.1038/ijo.2010.5.
DOI: 10.1038/ijo.2010.5

Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM Why are there race/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review. Obes Rev. 2016;17:262-275. https://doi.org/10.1111/obr.12358.
DOI: 10.1111/obr.12358

Rao G, Powell-Wiley TM, Ancheta I, Hairston K, Kirley K, Lear SA, North KE, Palaniappan L, Rosal MC; on behalf of the American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health. Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: a scientific statement from the American Heart Association [published correction appears in Circulation. 2015;132:e130]. Circulation. 2015;132:457-472. https://doi.org/10.1161/CIR.0000000000000223.
DOI: 10.1161/CIR.0000000000000223

Чазова И.Е. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями / И.Е. Чазова, Недогода С.В., Жернакова Ю.В. и др. Кардиологический вестник. 2014;1:3-57.

Дедов И.И., Шестакова М.В., Мельниченко Г.А., Мазурина Н.В., Андреева Е.Н. и соавт. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний» Ожирение и метаболизм. 2021;18(1):5-99. https://doi.org/10.14341/omet12714.
DOI: 10.14341/omet12714

Kim H, Caulfield LE, Rebholz CM. Healthy Plant-Based Diets Are Associated with Lower Risk of All-Cause Mortality in US Adults. J Nutr. 2018;148(4):624-631. https://doi.org/10.1093/jn/nxy019.
DOI: 10.1093/jn/nxy019

Satija A, Bhupathiraju SN, Spiegelman D, et al. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. J Am Coll Cardiol. 2017;70(4):411-422. https://doi.org/10.1016/j.jacc.2017.05.047.
DOI: 10.1016/j.jacc.2017.05.047

Sotos-Prieto M, Bhupathiraju SN, Mattei J, et al. Association of Changes in Diet Quality with Total and Cause Specific Mortality. N Engl J Med. 2017;377(2):143-153. https://doi.org/10.1056/NEJMoa1613502.
DOI: 10.1056/NEJMoa1613502

Alberti K.G. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation / K.G. Alberti, P.Z. Zimmet // Diabet Med. 1998;15:539.

Silver HJ, Welch EB, Avison MJ, Niswender KD: Imaging body composition in obesity and weight loss: challenges and opportunities. Diabetes Metab Syndr Obes 2010;3:337-347. https://doi.org/10.2147/dmsott.s9454.
DOI: 10.2147/dmsott.s9454

Bolanowski M, Nilsson BE: Assessment of human body composition using dual-energy x-ray absorptiometry and bioelectrical impedance analysis. Med Sci Monit 2001;7:1029-1033. PMID: 11535954

Cornier M-A, Després J-P, Davis N, Grossniklaus DA, Klein S, Lamarche B, Lopez-Jimenez F, Rao G, St-Onge M-P,Towfighi A, Poirier P; on behalf of the American Heart Association Obesity Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Radiology and Intervention,Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, Council on the Kidney in Cardiovascular Disease, and Stroke Council: Assessing adiposity: a scientific statement from the American Heart Association. Circulation 2011;124:1996-2019. https://doi.org/10.1161/CIR.0b013e318233bc6a.
DOI: 10.1161/CIR.0b013e318233bc6a

Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H; Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402-24. doi: 10.1159/000442721. Epub 2015 Dec 5. Erratum in: Obes Facts. 2016;9(1):64. PMID: 26641646; PMCID: PMC5644856..
DOI: 10.1159/000442721. Epub 2015 Dec 5. Erratum in: Obes Facts. 2016;9(1):64

LaForgia, J., Dollman, J., Dale, M.J., Withers, R.T. and Hill, A.M. (2009), Validation of DXA Body Composition Estimates in Obese Men and Women. Obesity, 17: 821-826. https://doi.org/10.1038/oby.2008.595.
DOI: 10.1038/oby.2008.595

Adult Obesity Algorithm eBook: Detailed overview of Obesity Medicine Bays HE, McCarthy W, Burridge K, Tondt J, Karjoo S, Christensen S, Ng J, Golden A, Davisson L, Richardson L. Obesity Algorithm eBook, presented by the Obesity Medicine Association. 2021; https://obesitymedicine.org/obesity-algorithm/ (Accessed = Insert date)https://obesitymedicine.org/obesity-algorithm/

Aragon, A.A., Schoenfeld, B.J., Wildman, R. et al. International society of sports nutrition position stand: diets and body composition. J Int Soc Sports Nutr. 14,16(2017). https://doi.org/10.1186/s12970-017-0174-y.
DOI: 10.1186/s12970-017-0174-y

Völgyi E, Tylavsky FA, Lyytikäinen A, Suominen H, Alén M, Cheng S. Assessing body composition with DXA and bioimpedance: effects of obesity, physical activity, and age. Obesity (Silver Spring). 2008 Mar;16(3):700-5. https://doi.org/10.1038/oby.2007.94. Epub 2008 Jan 17. PMID: 18239555..
DOI: 10.1038/oby.2007.94. Epub 2008 Jan 17

Fakhrawi DH, Beeson L, Libanati C, Feleke D, Kim H, Quansah A, Darnell A, Lammi-Keefe CJ, Cordero-MacIntyre Z. Comparison of body composition by bioelectrical impedance and dual-energy x-ray absorptiometry in overweight/obese postmenopausal women. J Clin Density. 2009 Apr-Jun; 12(2):238-44. https://doi.org/10.1016/j.jocd.2009.01.004. Epub 2009 Mar 13. PMID: 19285894..
DOI: 10.1016/j.jocd.2009.01.004. Epub 2009 Mar 13

Bray GA, DeLany JP, Volaufova J, Harsha DW, Champagne C. Prediction of body fat in 12-y-old African American and white children: evaluation of methods. Am J Clin Nutr. 2002 Nov;76(5):980-90. https://doi.org/10.1093/ajcn/76.5.980. PMID: 12399269..
DOI: 10.1093/ajcn/76.5.980

Hankinson SJ, Williams CH, Ton VK, Gottlieb SS, Hong CC. Should we overcome the resistance to bioelectrical impedance in heart failure? Expert Rev Med Devices. 2020 Aug;17(8):785-794. https://doi.org/10.1080/17434440.2020.1791701. Epub 2020 Jul 13. PMID: 32658589; PMCID: PMC8356137..
DOI: 10.1080/17434440.2020.1791701. Epub 2020 Jul 13

Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25;143(21):e984-e1010. https://doi.org/10.1161/CIR.0000000000000973. PMID: 33882682; PMCID: PMC8493650..
DOI: 10.1161/CIR.0000000000000973

Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management.Circulation. 2018;137:1391-1406. https://doi.org/10.1161/CIRCULATIONAHA.117.029617.
DOI: 10.1161/CIRCULATIONAHA.117.029617

Sjöström L. A computer-tomography based multicompartment body composition technique and anthropometric predictions of lean body mass, total and subcutaneous adipose tissue. Int J Obes. 1991 Sep;15 Suppl 2:19-30. PMID: 1794934.

Shah RV, Anderson A, Ding JZ, Budoff M, Rider O, Petersen SE, Jensen MK, Koch M, Allison M, Kawel-Boehm N, et al.. Pericardial, but not hepatic, fat by CT Is Associated With cv outcomes and structure: the Multi-Ethnic Study of Atherosclerosis.JACC Cardiovasc Imag. 2017;10:1016-1027. https://doi.org/10.1016/j.jcmg.2016.10.024.
DOI: 10.1016/j.jcmg.2016.10.024

Hruskova J, Maugeri A, Podrouzkova H, Stipalova T, Jakubik J, Barchitta M, Medina-Inojosa JR, Homolka M, Agodi A, Kunzova S, et al.. Association of cardiovascular health with epicardial adipose tissue and intima media thickness: the Kardiovize study.J Clin Med. 2018; 7:113. https://doi.org/10.3390/jcm7050113.
DOI: 10.3390/jcm7050113

Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk.J Clin Endocrinol Metab. 2003; 88:5163-5168. https://doi.org/10.1210/jc.2003-030698.
DOI: 10.1210/jc.2003-030698

Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O’Donnell CJ, Fox CS, Hoffmann U. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study.Eur Heart J. 2009; 30:850-856. https://doi.org/10.1093/eurheartj/ehn573.
DOI: 10.1093/eurheartj/ehn573

Ong KL, Ding J, McClelland RL, Cheung BM, Criqui MH, Barter PJ, Rye KA, Allison MA. Relationship of pericardial fat with lipoprotein distribution: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015;241:664-670. https://doi.org/10.1016/j.atherosclerosis.2015.06.027.
DOI: 10.1016/j.atherosclerosis.2015.06.027

Elming MB, Lønborg J, Rasmussen T, Kühl JT, Engstrøm T, Vejlstrup N, Køber L, Kofoed KF. Measurements of pericardial adipose tissue using contrast enhanced cardiac multidetector computed tomography-comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging. 2013 Aug;29(6):1401-7. https://doi.org/10.1007/s10554-013-0218-6. PMID: 23702948..
DOI: 10.1007/s10554-013-0218-6

Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010;92:1189-1196. https://doi.org/10.3945/ajcn.2010.29673.
DOI: 10.3945/ajcn.2010.29673

Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Fito M, Gea A, Hernan MA, Martinez-Gonzalez MA, PREDIMED Study Investigators. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 2018;378:e34. https://doi.org/10.1056/nejmoa1800389.
DOI: 10.1056/nejmoa1800389

Brader L, Uusitupa M, Dragsted LO, Hermansen K. Effects of an isocaloric healthy Nordic diet on ambulatory blood pressure in metabolic syndrome: a randomized SYSDIET sub-study. Eur J Clin Nutr 2014;68(1):57-63. https://doi.org/10.1038/ejcn.2013.192.
DOI: 10.1038/ejcn.2013.192

Mykkänen OT, Huotari A, Herzig KH et al. Wild blueberries (Vaccinium myrtillus) alleviate inflammation and hypertension associated with developing obesity in mice fed with a high-fat diet. PLoS One 2014;9(12):114790. https://doi.org/10.1371/journal.pone.0114790.
DOI: 10.1371/journal.pone.0114790

Erlund I, Koli R, Alfthan G et al. Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol. Am J Clin Nutr 2008; 87(2):323-31. https://doi.org/10.1093/ajcn/87.2.323.
DOI: 10.1093/ajcn/87.2.323

Yokoyama Y, Nishimura K, Barnard ND et al. Vegetarian diets and blood pressure: a meta-analysis. JAMA Intern Med 2014;174(4):577-87. https://doi.org/10.1001/jamainternmed.2013.14547.
DOI: 10.1001/jamainternmed.2013.14547

Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336(16):1117-24. https://doi.org/10.1056/nejm199704173361601.
DOI: 10.1056/nejm199704173361601

Pimenta E, Gaddam KK, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54 (3): 475–81. DOI: 10.1161/HYPERTENSIONAHA.109.131235.
DOI: 10.1161/HYPERTENSIONAHA.109.131235

Appel LJ, Espeland MA, Easter L et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001;161(5):685-93. https://doi.org/10.1001/archinte.161.5.685.
DOI: 10.1001/archinte.161.5.685

Cook NR, Cutler JA, Obarzanek E et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007;334(7599):885-8. https://doi.org/10.1136/bmj.39147.604896.55.
DOI: 10.1136/bmj.39147.604896.55

Chang HY, Hu YW, Yue CS et al. Effect of potassium-enriched salt on cardiovascular mortality and medical expenses of elderly men. Am J Clin Nutr 2006;83(6):1289-96. https://doi.org/10.1093/ajcn/83.6.1289.
DOI: 10.1093/ajcn/83.6.1289

He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 2011;378(9789):380-2. https://doi.org/10.1016/S0140-6736(11)61174-4.
DOI: 10.1016/S0140-6736(11)61174-4

Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: metaanalysis of prospective studies. BMJ 2009;339:b4567. https://doi.org/10.1136/bmj.b4567.
DOI: 10.1136/bmj.b4567

Frohlich ED. The salt conundrum: a hypothesis. Hypertension. 2007;50(1):161-6. https://doi.org/10.1161/hypertensionaha.107.088328.
DOI: 10.1161/hypertensionaha.107.088328

Streppel MT, Arends LR, van't Veer P et al. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med 2005;165(2):150-6. https://doi.org/10.1001/archinte.165.2.150.
DOI: 10.1001/archinte.165.2.150

Whelton SP, Hyre AD, Pedersen B et al. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens 2005;23(3):475-81. https://doi.org/10.1097/01.hjh.0000160199.51158.cf.
DOI: 10.1097/01.hjh.0000160199.51158.cf

Vernay M, Aïdara M, Salanave B et al. Diet and blood pressure in 18–74-year-old adults: the French Nutrition and Health Survey (ENNS, 2006-2007). J Hypertens 2012;30(10):1920-7. https://doi.org/10.1097/hjh.0b013e328356c59f.
DOI: 10.1097/hjh.0b013e328356c59f

Gopinath B, Flood VM, Rochtchina E et al. Influence of high glycemic index and glycemic load diets on blood pressure during adolescence. Hypertension 2012;59(6):1272-7. https://doi.org/10.1161/HYPERTENSIONAHA.112.190991.
DOI: 10.1161/HYPERTENSIONAHA.112.190991

Oude Griep LM, Stamler J, Chan Q, Van Horn L, Steffen LM, Miura K, Ueshima H, Okuda N, Zhao L, Daviglus ML, Elliott P; INTERMAP Research Group. Am J Clin Nutr. 2013 May;97(5):1083-91. https://doi.org/10.3945/ajcn.112.046300.
DOI: 10.3945/ajcn.112.046300

Hartley L, May MD, Loveman E et al. Dietary fibre for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2016;1:CD011472. https://doi.org/10.1002/14651858.CD011472.pub.
DOI: 10.1002/14651858.CD011472.pub

Bozzetto L, Costabile G, Della Pepa G et al. Dietary Fibre as a Unifying Remedy for the Whole Spectrum of Obesity-Associated Cardiovascular Risk. Nutrients 2018;10(7):pii:E943. https://doi.org/10.3390/nu10070943.
DOI: 10.3390/nu10070943

Smith CF, Williamson DA, Bray GA, Ryan DH. Flexible vs. Rigid dieting strategies: relationship with adverse behavioral outcomes. Appetite 1999; 32(3):295-305. https://doi.org/10.1006/appe.1998.0204.
DOI: 10.1006/appe.1998.0204

Stewart TM, Williamson DA, White MA. Rigid vs. flexible dieting: association with eating disorder symptoms in nonobese women. Appetite 2002;38(1):39-44. https://doi.org/10.1006/appe.2001.0445.
DOI: 10.1006/appe.2001.0445

Timko CA, Perone J. Rigid and flexible control of eating behavior in a college population. Eating behaviors 2005;6(2):119–25. https://doi.org/10.1016/j.eatbeh.2004.09.002.
DOI: 10.1016/j.eatbeh.2004.09.002

Westenhoefer J, Stunkard AJ, Pudel V. Validation of the flexible and rigid control dimensions of dietary restraint. Int J Eat Disord 1999;26(1):53-64. https://doi.org/10.1002/(sici)1098-108x(199907)26:1[%]3C53::aid-eat7[%]3E3.0.co;2-n.
DOI: 10.1002/(sici)1098-108x(199907)26:1[%]3C53::aid-eat7[%]3E3.0.co;2-n

Davoodi SH, Ajami M, Ayatollahi SA et al. Calorie Shifting Diet Versus Calorie Restriction Diet: A Comparative Clinical Trial Study. Int J Prev Med 2014;5(4):447-56. PMID: 24829732 PMCID: PMC4018593

Adamsson V, Reumark A, Fredriksson I-B et al. Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolemic subjects: a randomized controlled trial [NORDIET]. J Intern Med 2011; 269: 150–9.

Eilat-Adar S, Sinai T, Yosefy C, Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients 2013;5:36463683. https://doi.org/10.3390/nu5093646.
DOI: 10.3390/nu5093646

European Heart Network. Transforming European food and drink policies for cardiovascular health. http://www.ehnheart.org/publications-and-papers/publications/1093:transforming-european-food-and-drinks-policies-for-cardiovascular-health.html (21 July 2020).http://www.ehnheart.org/publications-and-papers/publications/1093:transforming-european-food-and-drinks-policies-for-cardiovascular-health.html

Mensink RP. Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis https://apps.who.int/iris/bitstream/handle/10665/246104/9789241565349-eng.pdf?sequence=1 (21 July 2020).https://apps.who.int/iris/bitstream/handle/10665/246104/9789241565349-eng.pdf?sequence=1

He FJ, Tan M, Ma Y, MacGregor GA. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:632-647. https://doi.org/10.1016/j.jacc.2019.11.055.
DOI: 10.1016/j.jacc.2019.11.055

Willett W, Rockstrom J, Loken B, Springmann M, Lang T, Vermeulen S, Garnett T, Tilman D, et al. Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from sustainable food systems. Lancet 2019;393:447-492. https://doi.org/10.1016/s0140-6736(18)31788-4.
DOI: 10.1016/s0140-6736(18)31788-4

Guasch-Ferre M, Satija A, Blondin SA, Janiszewski M, Emlen E, O’Connor LE, Campbell WW, Hu FB, Willett WC, Stampfer MJ. Meta-Analysis of Randomized Controlled Trials of Red Meat Consumption in Comparison With Various Comparison Diets on Cardiovascular Risk Factors. Circulation 2019;139:1828-1845. https://doi.org/10.1161/circulationaha.118.035225.
DOI: 10.1161/circulationaha.118.035225

Zeraatkar D, Johnston BC, Bartoszko J, Cheung K, Bala MM, Valli C, Rabassa M, Sit D, Milio K, Sadeghirad B, Agarwal A, Zea AM, Lee Y, Han MA, Vernooij RWM, Alonso-Coello P, Guyatt GH, El Dib R. Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic Review of Randomized Trials. Ann Intern Med 2019;171:721-731. https://doi.org/10.7326/m19-0622.
DOI: 10.7326/m19-0622

Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr 2012;15:725-737. https://doi.org/10.1017/s1368980011002254.
DOI: 10.1017/s1368980011002254

Mullee A, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, Freisling H, et al. Association Between Soft Drink Consumption and Mortality in 10 European Countries. JAMA Intern Med 2019;179:1479-1490. https://doi.org/10.1001/jamainternmed.2019.2478.
DOI: 10.1001/jamainternmed.2019.2478

World Health Organization. Guideline: sugars intake for adults and children. https://www.who.int/publications/i/item/9789241549028 (21 July 2020)https://www.who.int/publications/i/item/9789241549028

Howell S, Kones R. "Calories in, calories out" and macronutrient intake: the hope, hype, and science of calories. Am J Physiol Endocrinol Metab 2017;313:E608-E612. https://doi.org/10.1152/ajpendo.00156.2017.
DOI: 10.1152/ajpendo.00156.2017

Tobias DK, Chen M, Manson JE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015;3:968-979. https://doi.org/10.1016/S2213-8587(15)00367-8.
DOI: 10.1016/S2213-8587(15)00367-8

Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev 2016;17:1001-1011. https://doi.org/10.1111/obr.12433.
DOI: 10.1111/obr.12433

Wing RR, Espeland MA, Clark JM, Hazuda HP, Knowler WC, Pownall HJ, Unick J, Wadden T, Wagenknecht L, Action for Health in Diabetes (Look AHEAD) Study Group. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care 2016;39:1345-1355. https://doi.org/10.2337/dc16-0509.
DOI: 10.2337/dc16-0509

Doukky R, Mangla A, Ibrahim Z, et al. Impact of Physical Inactivity on Mortality in Patients With Heart Failure. Am J Cardiol. 2016;117(7):1135-1143. https://doi.org/10.1016/j.amjcard.2015.12.060.
DOI: 10.1016/j.amjcard.2015.12.060

Liu Y, Lee DC, Li Y, Zhu W, Zhang R, Sui X, Lavie CJ, Blair SN. Associations of Resistance Exercise with Cardiovascular Disease Morbidity and Mortality. Med Sci Sports Exerc 2019;51:499-508. https://doi.org/10.1249/mss.0000000000001822.
DOI: 10.1249/mss.0000000000001822

Saeidifard F, Medina-Inojosa JR, West CP, Olson TP, Somers VK, Bonikowske AR, Prokop LJ, Vinciguerra M, Lopez-Jimenez F. The association of resistance training with mortality: A systematic review and meta-analysis. Eur J Prev Cardiol 2019;26:1647-1665. https://doi.org/10.1177/2047487319850718.
DOI: 10.1177/2047487319850718

Ortega FB, Silventoinen K, Tynelius P, Rasmussen F. Muscular strength in male adolescents and premature death: cohort study of one million participants. BMJ 2012;345:e7279. https://doi.org/10.1136/bmj.e7279.
DOI: 10.1136/bmj.e7279

Volaklis KA, Halle M, Meisinger C. Muscular strength as a strong predictor of mortality: A narrative review. Eur J Intern Med 2015;26:303-310. https://doi.org/10.1016/j.ejim.2015.04.013.
DOI: 10.1016/j.ejim.2015.04.013

Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M, ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:1796. https://doi.org/10.1093/eurheartj/ehaa605.
DOI: 10.1093/eurheartj/ehaa605

Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP, American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011;43:1334-1359. https://doi.org/10.1249/mss.0b013e318213fefb.
DOI: 10.1249/mss.0b013e318213fefb

Kraus WE, Powell KE, Haskell WL, Janz KF, Campbell WW, Jakicic JM, Troiano RP, Sprow K, Torres A, Piercy KL, 2018 Physical Activity Guidelines Advisory Committee. Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease. Med Sci Sports Exerc 2019;51:1270-1281. https://doi.org/10.1249/mss.0000000000001939.
DOI: 10.1249/mss.0000000000001939

Powell KE, King AC, Buchner DM, Campbell WW, DiPietro L, Erickson KI, Hillman CH, Jakicic JM, Janz KF, Katzmarzyk PT, Kraus WE, Macko RF, Marquez DX, McTiernan A, Pate RR, Pescatello LS, Whitt-Glover MC. The Scientific Foundation for the Physical Activity Guidelines for Americans, 2nd Edition. J Phys Act Health 2018:111. https://doi.org/10.1123/jpah.2018-0618.
DOI: 10.1123/jpah.2018-0618

Sattelmair J, Pertman J, Ding EL, Kohl HW, 3rd, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 2011;124:789-795. https://doi.org/10.1161/circulationaha.110.010710.
DOI: 10.1161/circulationaha.110.010710

Hupin D, Roche F, Gremeaux V, Chatard JC, Oriol M, Gaspoz JM, Barthelemy JC, Edouard P. Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22[%] in adults aged >/=60 years: a systematic review and meta-analysis. Br J Sports Med 2015;49:1262-1267. http://dx.doi.org/10.1136/bjsports-2014-094306.
DOI: 10.1136/bjsports-2014-094306

Cradock KA, OL G, Finucane FM, Gainforth HL, Quinlan LR, Ginis KA. Behaviour change techniques targeting both diet and physical activity in type 2 diabetes: A systematic review and meta-analysis. Int J Behav Nutr Phys Act 2017;14:18. https://doi.org/10.1186/s12966-016-0436-0.
DOI: 10.1186/s12966-016-0436-0

Brickwood KJ, Watson G, O’Brien J, Williams AD. Consumer-Based Wearable Activity Trackers Increase Physical Activity Participation: Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth 2019;7:e11819. https://doi.org/10.2196/11819.
DOI: 10.2196/11819

Torgeson J.S., Hauptman J. XENical in the prevention of diabetes in obese subjects subjects (XENDOS) study. Diabetes Care. 2004;27:155-161. https://doi.org/10.2337/diacare.27.1.155.
DOI: 10.2337/diacare.27.1.155

Rossner S., Sjostrom L., Noack R. et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.Obes. Res. 2000;8(1): 49-61. https://doi.org/10.1038/oby.2000.8.
DOI: 10.1038/oby.2000.8

Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med.2015;373(1):11-22. https://doi.org/10.1056/NEJMoa1411892.
DOI: 10.1056/NEJMoa1411892

le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double-blind trial. Lancet. 2017;389(10077):1399-1409. https://doi.org/10.1016/s0140-6736(17)30069-7.
DOI: 10.1016/s0140-6736(17)30069-7

Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. https://doi.org/10.1038/ij o.2016.52.
DOI: 10.1038/ij o.2016.52

Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity. 2013;37:1443-1451; https://doi.org/10.1038/ijo.2013.120.
DOI: 10.1038/ijo.2013.120

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. https://doi.org/10.1056/NEJMoa1603827.
DOI: 10.1056/NEJMoa1603827

TA Wadden, P Hollander, S Klein et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity. 2013;37:1443-1451; https://doi.org/10.1038/ijo.2013.120.
DOI: 10.1038/ijo.2013.120

legal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a sys- tematic review and meta-analysis. JAMA 2013;309:71-82. https://doi.org/10.1001/jama.2012.113905.
DOI: 10.1001/jama.2012.113905

Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju Sh N, Wormser D, Gao P, et al. Body-mass index and all-cause mortality: individual- participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-786. https://doi.org/10.1016/s0140-6736(16)30175-1.
DOI: 10.1016/s0140-6736(16)30175-1

Rucker D., Padwal R., Li S. et al. Long term pharmacotherapy for obesity and overweight updated meta-analysis. British Medical Journal 2007; 335: 1194-1199.

Avenell A., Broom J., Brown T. et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004, May;8(21):iii-iv,1-182. https://doi.org/10.3310/hta8210.
DOI: 10.3310/hta8210

Biddle SJH, Bengoechea García E, Pedisic Z, et al. Screen Time, Other Sedentary Behaviours, and Obesity Risk in Adults: A Review of Reviews. Curr Obes Rep. 2017;6(2):134-147. https://doi.org/10.1007/s13679-017-0256-9.
DOI: 10.1007/s13679-017-0256-9

Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. Longo DL, ed. N Engl J Med. 2017;376(3):254-266. https://doi.org/10.1056/NEJMra1514009.
DOI: 10.1056/NEJMra1514009

Guh DP, Zhang W, Bansback N, et al. The incidence of comorbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9:88. https://doi.org/10.1186/1471-2458-9-88.
DOI: 10.1186/1471-2458-9-88

Lenz M, Richter T, Mühlhauser I. The Morbidity and Mortality Associated With Overweight and Obesity in Adulthood. Dtsch Aerzteblatt Online. 2009;106:641-648. doi: https://doi.org/10.3238/arztebl.2009.0641.
DOI: 10.3238/arztebl.2009.0641

Cardoso L, Rodrigues D, Gomes L, Carrilho F. Short- and long-term mortality after bariatric surgery: A systematic review and meta-analysis. Diabetes Obes Metab 2017;19:1223-1232. https://doi.org/10.1111/dom.12922.
DOI: 10.1111/dom.12922

Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97. https://doi.org/10.1001/jama.290.1.86.
DOI: 10.1001/jama.290.1.86

Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-239. https://doi.org/10.7326/0003-4819-142-4-200502150-00005.
DOI: 10.7326/0003-4819-142-4-200502150-00005

Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018;5:CD000146. https://doi.org/10.1002/14651858.cd000146.pub5.
DOI: 10.1002/14651858.cd000146.pub5

Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007:CD000031. https://doi.org/10.1002/14651858.cd000031.pub4.
DOI: 10.1002/14651858.cd000031.pub4

Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016:CD006103. https://doi.org/10.1002/14651858.cd006103.pub7.
DOI: 10.1002/14651858.cd006103.pub7

Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2019;4:CD013308. https://doi.org/10.1002/14651858.cd013308.
DOI: 10.1002/14651858.cd013308

Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano JD. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol 2012;110:968-970. https://doi.org/10.1016/j.amjcard.2012.05.028.
DOI: 10.1016/j.amjcard.2012.05.028

Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR, Baril JF, Lambert C, Madan M, Abramson BL, Dehghani P, EVITA Investigators. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. Circulation 2016;133:21-30. https://doi.org/10.1161/circulationaha.115.019634.
DOI: 10.1161/circulationaha.115.019634

Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med 2018;178:622-631. https://doi.org/10.1001/jamainternmed.2018.0397.
DOI: 10.1001/jamainternmed.2018.0397

Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, Joseph L, Reynier PM, Filion KB. Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes 2017;10:e002458. https://doi.org/10.1161/circoutcomes.115.002458.
DOI: 10.1161/circoutcomes.115.002458

Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu FB, Sun Q. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med 2018;379:623-632. https://doi.org/10.1056/nejmoa1803626.
DOI: 10.1056/nejmoa1803626

Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, et al. Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:1513-1523. https://doi.org/10.1016/s0140-6736(18)30134-x.
DOI: 10.1016/s0140-6736(18)30134-x

Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, Bennett DA, Chen Y, Dong C, Hu R, Zhou G, Yu B, Jia W, Parish S, Clarke R, Davey Smith G, Collins R, Holmes MV, Li L, Peto R, Chen Z, China Kadoorie Biobank Collaborative Group. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. Lancet 2019;393:1831-1842. http://doi.org/10.1016/S0140-6736(18)31772-0.
DOI: 10.1016/S0140-6736(18)31772-0

Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, Prieto-Merino D, Dehghan A, Trompet S, Wong A, Cavadino A, Drogan D, et al. InterAct Consortium. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014;349:g4164. https://doi.org/10.1136/bmj.g4164.
DOI: 10.1136/bmj.g4164

Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B, Kindermann I, Kollner V, Leithauser B, Marx N, Meesmann M, Michal M, Ronel J, Scherer M, Schrader V, Schwaab B, Weber CS, Herrmann-Lingen C. Significance of psycho-social factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol 2019;108:1175-1196. https://doi.org/10.1007/s00392-019-01488-w.
DOI: 10.1007/s00392-019-01488-w

Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M, Duncker DJ, Koller A, Manfrini O, Milicic D, Padro T, Pries AR, Quyyumi AA, Tousoulis D, Trifunovic D, Vasiljevic Z, de Wit C, Bugiardini R, ESC Scientific Document Group Reviewers. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J 2020;41:1687-1696. https://doi.org/10.1093/eurheartj/ehy913.
DOI: 10.1093/eurheartj/ehy913

Petersen BD, Stenager E, Mogensen CB, Erlangsen A. The association between heart diseases and suicide: a nationwide cohort study. J Intern Med 2020;287:558-568. https://doi.org/10.1111/joim.13025.
DOI: 10.1111/joim.13025

Albert MA, Glynn RJ, Buring J, Ridker PM. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation 2006;114:2619-2626. https://doi.org/10.1161/circulationaha.106.660043.
DOI: 10.1161/circulationaha.106.660043

Alter DA, Franklin B, Ko DT, Austin PC, Lee DS, Oh PI, Stukel TA, Tu JV. Socioeconomicstatus, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS One 2013;8(6):e65130. https://doi.org/10.1371/journal.pone.0065130.
DOI: 10.1371/journal.pone.0065130

Berntson J, Patel JS, Stewart JC. Number of recent stressful life events and incident cardiovascular disease: Moderation by lifetime depressive disorder. J Psychosom Res 2017; 99: 149-154. https://doi.org/10.1016/j.jpsychores.2017.06.008. Epub 2017 Jun 12..
DOI: 10.1016/j.jpsychores.2017.06.008. Epub 2017 Jun 12

Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Hofer S, Doyle F, Schmid JP, von Kanel R. Psychosocial aspects in cardiac rehabilitation: from theoryto practice. A position paper from the Cardiac Rehabilitation Section of the EuropeanAssociation of Cardiovascular Prevention and Rehabilitation of the EuropeanSociety of Cardiology. Eur J Prev Cardiol 2015;22:1290-1306. https://doi.org/10.1177/2047487314543075.
DOI: 10.1177/2047487314543075

Roest AM, Martens EJ, Denollet J, et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: A metaanalysis. Psychosom Med 2010;72:563-569. https://doi.org/10.1097/psy.0b013e3181dbff97.
DOI: 10.1097/psy.0b013e3181dbff97

Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, ObermanA,Wong ND, Sheps D. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women’s Health Initiative Observational Study. Arch Gen Psychiatry 2007;64:1153-1160. https://doi.org/10.1001/archpsyc.64.10.1153.
DOI: 10.1001/archpsyc.64.10.1153

Albus C, Jordan J, Herrmann-Lingen C. Screening for psychosocial risk factors in patients with coronary heart disease-recommendations for clinical practice. Eur J Cardiovasc Prev Rehabil 2004;11:75-79. https://doi.org/10.1097/01.hjr.0000116823.84388.6c.
DOI: 10.1097/01.hjr.0000116823.84388.6c

Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 2011;171:134-140. https://doi.org/10.1001/archinternmed.2010.510.
DOI: 10.1001/archinternmed.2010.510

Orth-Gomer K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes 2009;2(1):25-32. https://doi.org/10.1161/circoutcomes.108.812859.
DOI: 10.1161/circoutcomes.108.812859

Dickens C, Cherryington A, Adeyemi I, Roughley K, Bower P, Garrett C, Bundy C, Coventry P. Characteristics of psychological interventions that improve depression in people with coronary heart disease: a systematic review and meta-regression. Psychosom Med 2013;75(2):211-221. https://doi.org/10.1097/psy.0b013e31827ac009.
DOI: 10.1097/psy.0b013e31827ac009

Бойцов С.А., Погосова Н.В., Бубнова М.Г., Драпкина О.М. и соавт. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российское кардиологическое общество, Национальное общество профилактической кардиологии, Российское общество профилактики неинфекционных заболеваний. Российский кардиологический журнал. 2018;23(6):7-122. http://dx.doi.org/10.15829/1560-4071-2018-6-7-122.
DOI: 10.15829/1560-4071-2018-6-7-122

Blumenthal JA, Sherwood A, Smith PJ, Watkins L, Mabe S, Kraus WE, Ingle K, Miller P, Hinderliter A. Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial. Circulation 2016;133:1341-1350. https://doi.org/10.1161/circulationaha.115.018926.
DOI: 10.1161/circulationaha.115.018926

He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev 2020;25:919-926. https://doi.org/10.1007/s10741-019-09850-w.
DOI: 10.1007/s10741-019-09850-w

Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R, Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S, Prettin C, Gottwik M, Bohm M, Faller H, Deckert J, Ertl G, MOOD-HF Study Investigators and Committee Members. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA 2016;315:2683-2693. https://doi.org/10.1001/jama.2016.7635.
DOI: 10.1001/jama.2016.7635

Michael J Sateia, International Classification of Sleep Disorders-Third Edition, Chest, 2014 Nov;146(5):1387-1394, ISSN 0012-3692, https://doi.org/10.1378/chest.14-0970.
DOI: 10.1378/chest.14-0970

Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999 Aug 1;22(5):667-89. PMID: 10450601.

Young T, Palta M, Dempsey J, et al. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. Wis- consin Medical J. 2009;108(5):246-9. PMID: 19743755

Lopez PP, Stefan B, Schulman CI, et al. Prevalence of sleep apnea in morbidly obese patients who presented for weight loss surgery evaluation: more evidence for routine screening for obstructive sleep apnea before weight loss surgery. Am Surg 2008;74:834-8. PMID: 18807673

Peppard PE, Ward NR, Morrell MJ. The impact of obesity on oxygen desaturation during sleep-disordered breathing. Am J Respir Crit Care Med 2009;180:788-793. https://doi.org/10.1164/rccm.200905-0773oc.
DOI: 10.1164/rccm.200905-0773oc

Redline S, Schluchter MD, Larkin EK, Tishler PV. Predictors of longitudinal change in sleep-disordered breathing in a nonclinic population. Sleep 2003;26:703-70. https://doi.org/10.1093/sleep/26.6.703.
DOI: 10.1093/sleep/26.6.703

Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, Mehra R, Bozkurt B, Ndumele CE, Somers VK. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-e67. doi: 10.1161/CIR.0000000000000988. Epub 2021 Jun 21. Erratum in: Circulation. 2022 Mar 22;145(12):e775. PMID: 34148375. https://doi.org/10.1161/cir.0000000000000988.
DOI: 10.1161/cir.0000000000000988

Leinum CJ, Dopp JM, Morgan BJ. Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment. Nutr Clin Pract. 2009 Dec;24(6):675-87. PMID: 19955545; PMCID: PMC2873205. https://doi.org/10.1177/0884533609351532.
DOI: 10.1177/0884533609351532

Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479-504. https://doi.org/10.5664/jcsm.6506.
DOI: 10.5664/jcsm.6506

Hudgel DW, Patel SR, Ahasic AM, Bartlett SJ, Bessesen DH, Coaker MA, Fiander PM, Grunstein RR, Gurubhagavatula I, Kapur VK, Lettieri CJ, Naughton MT, Owens RL, Pepin JL, Tuomilehto H, Wilson KC; American Thoracic Society Assembly on Sleep and Respiratory Neurobiology. The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Sep 15;198(6):e70-e87. PMID: 30215551. https://doi.org/10.1164/rccm.201807-1326ST.
DOI: 10.1164/rccm.201807-1326ST

Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014 Feb 22;383(9918):736-47. doi: 10.1016/S0140-6736(13)60734-5. Epub 2013 Aug 2. PMID: 23910433; PMCID: PMC3909558..
DOI: 10.1016/S0140-6736(13)60734-5. Epub 2013 Aug 2

Jonas DE, Amick HR, Feltner C, Weber RP, Arvanitis M, Stine A, Lux L, Harris RP Screening for Obstructive Sleep Apnea in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017;317(4):415. PMID: 28211654

Giles TL, Lasserson TJ, Smith BJ, White J, Wright J, Cates CJ Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001106. https://doi.org/10.1002/14651858.cd001106.pub2.
DOI: 10.1002/14651858.cd001106.pub2

Walia HK, Thompson NR, Pascoe M, Faisal M, Moul DE, Katzan I, Mehra R, Foldvary-Schaefer N Effect of Positive Airway Pressure Therapy on Drowsy Driving in a Large Clinic-Based Obstructive Sleep Apnea Cohort. J Clin Sleep Med. 2019;15(11):1613-1620. https://doi.org/10.5664/jcsm.8024.
DOI: 10.5664/jcsm.8024

Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2019;15(2):335-343. https://doi.org/10.5664/jcsm.7640.
DOI: 10.5664/jcsm.7640

Аксенова А.В., Сивакова О.А., Блинова Н.В., Данилов Н.М. и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии по диагностике и лечению резистентной артериальной гипертонии. Терапевтический архив. 2021;93(9):1018-1029. https://doi.org/10.26442/00403660.2021.09.201007.
DOI: 10.26442/00403660.2021.09.201007

Mokhlesi B, Masa JF, Brozek JL, Gurubhagavatula I, et al. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 Aug 1;200(3):e6-e24. Erratum in: Am J Respir Crit Care Med. 2019 Nov 15;200(10):1326. PMID: 31368798; PMCID: PMC6680300. https://doi.org/10.1164/rccm.201905-1071ST.
DOI: 10.1164/rccm.201905-1071ST

Nowbar S, Burkart KM, Gonzales R, Fedorowicz A, Gozansky WS, Gaudio JC, Taylor MR, Zwillich CW. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004 Jan 1;116(1):1-7. https://doi.org/10.1016/j.amjmed.2003.08.022 PMID: 14706658..
DOI: 10.1016/j.amjmed.2003.08.022

Mokhlesi B. Obesity hypoventilation syndrome: a state-of-the-art review. Respir Care. 2010 Oct;55(10):1347-62; discussion 1363-5. PMID: 20875161

Chau EH, Lam D, Wong J, Mokhlesi B, Chung F, Obesity hypoventilation syndrome: a review of epidemiology, pathophysiology, and perioperative considerations, Anesthesiology. 2012 Jul;117(1):188-205. https://doi.org/10.1097/aln.0b013e31825add60.
DOI: 10.1097/aln.0b013e31825add60

Lecube A, Sampol G, Lloberes P, Romero O, Mesa J, Morell F, SimóR, Asymptomatic sleep-disordered breathing in premenopausal women awaiting bariatric surgery. Obes Surg. 2010 Apr;20(4):454-61. Epub 2009 Dec 18. https://doi.org/10.1007/s11695-009-0033-2.
DOI: 10.1007/s11695-009-0033-2

Domínguez-Cherit G, Gonzalez R, Borunda D, Pedroza J, Gonzalez-Barranco J, Herrera MF, Anesthesia for morbidly obese patients. World J Surg. 1998;22(9):969. https://doi.org/10.1007/s002689900501.
DOI: 10.1007/s002689900501

Nowbar S, Burkart KM, Gonzales R, Fedorowicz A, Gozansky WS, Gaudio JC, Taylor MR, Zwillich CW. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004;116(1):1. https://doi.org/10.1016/j.amjmed.2003.08.022.
DOI: 10.1016/j.amjmed.2003.08.022

Шарипова Г.М. Особенности поражения органов-мишеней у больных артериальной гипертонией в зависимости от наличия и отсутствия метаболического синдрома. Дисс. д.м.н., М., 2009.

Жернакова Ю.В. Клиническая характеристика различных вариантов течения метаболического синдрома и возможности влияния антигипертензивной терапии на уровень артериального давления, состояние углеводного, липидного обменов и выраженность ожирения у больных артериальной гипертонией и метаболическим синдромом. Дисс. д.м.н., М., 2012.

И. Е. Чазова, Ю.В. Жернакова от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16(1): 6-31.

De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. Prog Cardiovasc Dis 2008; 50:238–263. https://doi.org/10.1016/j.pcad.2007.08.001.
DOI: 10.1016/j.pcad.2007.08.001

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual datafor one million adults in 61 prospective studies. Lancet 2002; 360:1903–1913. https://doi.org/10.1016/s0140-6736(02)11911-8.
DOI: 10.1016/s0140-6736(02)11911-8

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017;35:922–944. https://doi.org/10.1097/hjh.0000000000001276.
DOI: 10.1097/hjh.0000000000001276

D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743–753. https://doi.org/10.1161/circulationaha.107.699579.
DOI: 10.1161/circulationaha.107.699579

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33:1635–1701. https://doi.org/10.1093/eurheartj/ehs092.
DOI: 10.1093/eurheartj/ehs092

Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward M, Neal B, Blood Pressure-Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184–191. https://doi.org/10.7326/m14-0773.
DOI: 10.7326/m14-0773

Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med 2018;178:28–36. https://doi.org/10.1001/jamainternmed.2017.6015.
DOI: 10.1001/jamainternmed.2017.6015

Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290–300. https://doi.org/10.1016/j.amjmed.2008.09.038.
DOI: 10.1016/j.amjmed.2008.09.038

MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes G, Brown MJ, British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017;6:e006986. https://doi.org/10.1161/jaha.117.006986.
DOI: 10.1161/jaha.117.006986

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens 2016;34:1921-1932. https://doi.org/10.1097/hjh.0000000000001052.
DOI: 10.1097/hjh.0000000000001052

Yusuf S, Lonn E, Pais P, Bosch J, Lopez-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, Dagenais G, HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374: 2032-2043. https://doi.org/10.1056/nejmoa1600177.
DOI: 10.1056/nejmoa1600177

Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26:819-824. https://doi.org/10.1097/hjh.0b013e3282f4edd7.
DOI: 10.1097/hjh.0b013e3282f4edd7

Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407. https://doi.org/10.1161/hypertensionaha.109.139816.
DOI: 10.1161/hypertensionaha.109.139816

Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ III, Graff A, Shojaee A, Waverczak WF, Qian C, Jones CJ, Neutel JM. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011;13:404–412. https://doi.org/10.1111/j.1751-7176.2011.00437.x.
DOI: 10.1111/j.1751-7176.2011.00437.x

Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012;32:649-664. https://doi.org/10.1007/bf03261919.
DOI: 10.1007/bf03261919

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-2068. https://doi.org/10.1016/s0140-6736(15)00257-3.
DOI: 10.1016/s0140-6736(15)00257-3

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-967. https://doi.org/10.1016/s0140-6736(15)01225-8.
DOI: 10.1016/s0140-6736(15)01225-8

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015;33:1321-1341. https://doi.org/10.1097/hjh.0000000000000614.
DOI: 10.1097/hjh.0000000000000614

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 2016;34:613-622. https://doi.org/10.1097/hjh.0000000000000881.
DOI: 10.1097/hjh.0000000000000881

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials. J Hypertens 2014;32:2296-2304. https://doi.org/10.1097/hjh.0000000000000379.
DOI: 10.1097/hjh.0000000000000379

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021-3104. https://doi.org/10.1093/eurheartj/ehy339.
DOI: 10.1093/eurheartj/ehy339

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-443. https://doi.org/10.1016/s0140-6736(15)00805-3.
DOI: 10.1016/s0140-6736(15)00805-3

Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389(10085):2226-2237. https://doi.org/10.1016/S0140-6736(17)30754-7.
DOI: 10.1016/S0140-6736(17)30754-7

Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press. 2016;25(2):83-92. https://doi.org/10.3109/08037051.2015.1106750.
DOI: 10.3109/08037051.2015.1106750

Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37(12):955-964. https://doi.org/10.1093/eurheartj/ehv633.
DOI: 10.1093/eurheartj/ehv633

SPRINT Research Group, et al. A Randomized Trial of Intensive versus Standard BloodPressure Control. N Engl J Med. 2015;373(22):2103-2116. https://doi.org/10.1056/NEJMoa1511939.
DOI: 10.1056/NEJMoa1511939

Tsai W-C, Wu H-Y, Peng Y-S, et al. Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease. JAMA Intern Med. 2017;177(6):792. https://doi.org/10.1001/jamainternmed.2017.0197.
DOI: 10.1001/jamainternmed.2017.0197

Jafar TH, Stark PC, Schmid CH, et al. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. Ann Intern Med. 2003;139(4):244. https://doi.org/10.7326/0003-4819-139-4-200308190-00006.
DOI: 10.7326/0003-4819-139-4-200308190-00006

Sim JJ, Shi J, Kovesdy CP, et al. Impact of Achieved Blood Pressures on Mortality Risk and End-Stage Renal Disease Among a Large, Diverse Hypertension Population. J Am Coll Cardiol. 2014;64(6):588- 597. https://doi.org/10.1016/j.jacc.2014.04.065.
DOI: 10.1016/j.jacc.2014.04.065

Owen JG, Reisin E. Anti-hypertensive Drug Treatment of Patients with and the Metabolic Syndrome and Obesity: a Review of Evidence, Meta-Analysis, Post hoc and Guidelines Publications. Curr Hypertens Rep. 2015;17(6):46. https://doi.org/10.1007/s11906-015-0558-9.
DOI: 10.1007/s11906-015-0558-9

Tocci G, Paneni F, Palano F, et al. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A MetaAnalysis of Placebo-Controlled Clinical Trials. Am J Hypertens. 2011;24(5):582-590. https://doi.org/10.1038/ajh.2011.8.
DOI: 10.1038/ajh.2011.8

Abuissa H, Jones PG, Marso SP, O’Keefe JH. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes. J Am Coll Cardiol. 2005;46(5):821-826. https://doi.org/10.1016/j.jacc.2005.05.051.
DOI: 10.1016/j.jacc.2005.05.051

Yang Y, Wei R, Xing Y, et al. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients. Metabolism. 2013;62(12):1858-1866. https://doi.org/10.1016/j.metabol.2013.08.008.
DOI: 10.1016/j.metabol.2013.08.008

NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490. https://doi.org/10.1056/nejmoa1001121.
DOI: 10.1056/nejmoa1001121

Скибицкий В.В. и др. Антигипертензивные и вазопротективные эффекты комбинированной фармакотерапии у пациентов с артериальной гипертензией и предиабетом. Кардиология, 2020;60(4). https://doi.org/10.18087/cardio.2020.4.n1112.
DOI: 10.18087/cardio.2020.4.n1112

Abellán J et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl. 2005, Jan;(93):S20-4. https://doi.org/10.1111/j.1523-1755.2005.09305.x.
DOI: 10.1111/j.1523-1755.2005.09305.x

Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens 2004 Sep; 18 (9): 669-75. https://doi.org/10.1038/sj.jhh.1001676.
DOI: 10.1038/sj.jhh.1001676

McGill H. Fatty streaks in the coronary arteries and aorta. Lab Invest. 1968;560-4. PMID: 5681198

Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman III WP, Herderick EE, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. Jama. 1999;281(8):727-35. https://doi.org/10.1001/jama.281.8.727.
DOI: 10.1001/jama.281.8.727

McGill Jr HC, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105(23):2712-8. https://doi.org/10.1161/01.cir.0000018121.67607.ce.
DOI: 10.1161/01.cir.0000018121.67607.ce

Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338(23):1650-6. https://doi.org/10.1056/nejm199806043382302.
DOI: 10.1056/nejm199806043382302

McGill Jr HC, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 1995;15(4):431-40. https://doi.org/10.1161/01.atv.15.4.431.
DOI: 10.1161/01.atv.15.4.431

Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med. 2002;21(2):213-37. https://doi.org/10.1080/15227950252852104.
DOI: 10.1080/15227950252852104

Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6(6):399-409. https://doi.org/10.1038/nrcardio.2009.55.
DOI: 10.1038/nrcardio.2009.55

Ross R. Pathogenesis of atherosclerosis-atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5):S419. https://doi.org/10.1016/s0002-8703(99)70266-8.
DOI: 10.1016/s0002-8703(99)70266-8

Couillard C, Ruel G, Archer WR, Pomerleau S, Bergeron J, Couture P, et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab. 2005;90(12):6454–9. https://doi.org/10.1210/jc.2004-2438.
DOI: 10.1210/jc.2004-2438

Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364–73. https://doi.org/10.1016/j.tcm.2015.10.004.
DOI: 10.1016/j.tcm.2015.10.004

Engin A. Endothelial dysfunction in obesity. Obes lipotoxicity. 2017;345–79. https://doi.org/10.1007/978-3-319-48382-5_15.
DOI: 10.1007/978-3-319-48382-5_15

Calle EE, Thun MJ, Petrelli JM, Rodriguez C. Health, CW Jr. Body-mass index Mortal a Prospect cohort US adults. 1994;1097–104.

Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968–77. https://doi.org/10.1161/01.cir.67.5.968.
DOI: 10.1161/01.cir.67.5.968

Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. N Engl J Med. 1995;333(11):677–85.

Folsom AR, Stevens J, Schreiner PJ, McGovern PG, Investigators AR in CS. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Am J Epidemiol. 1998;148(12):1187–94.

Bogers RP, Bemelmans WJE, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007;167(16):1720–8.

Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek J, et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J. 2010;31(6):737–46.

Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al. Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med. 2015;163(11):827–35.

Coutinho T, Goel K, Corrêa de Sá D, Carter RE, Hodge DO, Kragelund C, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of “normal weight central obesity.” J Am Coll Cardiol. 2013;61(5):553–60.

Canoy D, Cairns BJ, Balkwill A, Wright FL, Green J, Reeves G, et al. Coronary heart disease incidence in women by waist circumference within categories of body mass index. Eur J Prev Cardiol. 2013;20(5):759–62.

Ndumele CE, Matsushita K, Lazo M, Bello N, Blumenthal RS, Gerstenblith G, et al. Obesity and subtypes of incident cardiovascular disease. J Am Heart Assoc. 2016;5(8):e003921.

Wilson PWF, Bozeman SR, Burton TM, Hoaglin DC, Ben-Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation. 2008;118(2):124–30.

Mørkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway. J Am Coll Cardiol. 2014;63(11):1071–8.

Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med. 2014;174(1):15–22.

Lassale C, Tzoulaki I, Moons KGM, Sweeting M, Boer J, Johnson L, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J. 2018;39(5):397–406.

Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective coh. Lancet. 2014;383(9921):970–83.

Himabukuro M, Hirata Y, Tabata M, Dagvasumberel M, Sato H, Kurobe H, et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33(5):1077–84.

Ishii T, Asuwa N, Masuda S, Ishikawa Y. The effects of a myocardial bridge on coronary atherosclerosis and ischaemia. J Pathol A J Pathol Soc Gt Britain Irel. 1998;185(1):4–9.

Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging. 2010;3(6):623–40.

Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(21):2625–41.

Lee B-K, Lim H-S, Fearon WF, Yong AS, Yamada R, Tanaka S, et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015;131(12):1054–60.

Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015;131(1):19–27.

Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang X-L, et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol. 2006;47(6):1188–95.

Bajaj NS, Osborne MT, Gupta A, Tavakkoli A, Bravo PE, Vita T, et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients. J Am Coll Cardiol. 2018;72(7):707–17.

Quercioli A, Montecucco F, Pataky Z, Thomas A, Ambrosio G, Staub C, et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J. 2013;34(27):2063–73.

Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–1010.

Snelder SM, van de Poll SWE, de Groot–de Laat LE, Kardys I, Zijlstra F, van Dalen BM. Optimized electrocardiographic criteria for the detection of left ventricular hypertrophy in obesity patients. Clin Cardiol. 2020;43(5):483–90.

Peguero JG, Lo Presti S, Perez J, Issa O, Brenes JC, Tolentino A. Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy. J Am Coll Cardiol. 2017;69(13):1694–703.

Karason K, Lindroos AK, Stenlöf K, Sjöström L. Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study. Arch Intern Med. 2000;160(12):1797–802.

Chrysohoou C, Skoumas J, Georgiopoulos G, Liontou C, Vogiatzi G, Tsioufis K, et al. Exercise capacity and haemodynamic response among 12,327 individuals with cardio-metabolic risk factors undergoing treadmill exercise. Eur J Prev Cardiol. 2017;24(15):1627–36.

Bires AM, Lawson D, Wasser TE, Raber-Baer D. Comparison of Bruce treadmill exercise test protocols: is ramped Bruce equal or superior to standard bruce in producing clinically valid studies for patients presenting for evaluation of cardiac ischemia or arrhythmia with body mass index equal to or grea. J Nucl Med Technol. 2013;41(4):274–8.

Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280–7.

Elagizi A, Kachur S, Lavie CJ, Carbone S, Pandey A, Ortega FB, et al. An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. Prog Cardiovasc Dis[Internet].2018;61(2):142–50. Available from: https://www.sciencedirect.com/science/article/pii/S0033062018301300https://www.sciencedirect.com/science/article/pii/S0033062018301300

Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2018;61(2):151–6.

Bassi N, Karagodin I, Wang S, Vassallo P, Priyanath A, Massaro E, et al. Lifestyle modification for metabolic syndrome: a systematic review. Am J Med. 2014;127(12):1242-e1.

Lien LF, Brown AJ, Ard JD, Loria C, Erlinger TP, Feldstein AC, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007;50(4):609–16.

Group LAR. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.

Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. bmj. 2017;359.

Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Thomas RJ, Squires RW, et al. Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Prev Cardiol. 2008;15(3):336–40.

Batsis JA, Sarr MG, Collazo-Clavell ML, Thomas RJ, Romero-Corral A, Somers VK, et al. Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol. 2008;102(7):930–7.

Payvar S, Kim S, Rao S V, Krone R, Neely M, Paladugu N, et al. In-hospital outcomes of percutaneous coronary interventions in extremely obese and normal-weight patients: findings from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2013;62(8):692–6.

Joncas SX, Poirier P, Ardilouze J, Carrier N, Fayad T, Farand P. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome. Obesity. 2013;21(9):1753–8.

Buschur ME, Smith D, Share D, Campbell W, Mattichak S, Sharma M, et al. The burgeoning epidemic of morbid obesity in patients undergoing percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J Am Coll Cardiol. 2013;62(8):685–91.

Holroyd EW, Sirker A, Kwok CS, Kontopantelis E, Ludman PF, De Belder MA, et al. The relationship of body mass index to percutaneous coronary intervention outcomes: does the obesity paradox exist in contemporary percutaneous coronary intervention cohorts? Insights from the British Cardiovascular Intervention Society Registry. JACC Cardiovasc Interv. 2017;10(13):1283–92.

Terada T, Forhan M, Norris CM, Qiu W, Padwal R, Sharma AM, et al. Differences in short‐and long‐term mortality associated with BMI following coronary revascularization. J Am Heart Assoc. 2017;6(4):e005335.

Lancefield T, Clark DJ, Andrianopoulos N, Brennan AL, Reid CM, Johns J, et al. Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. JACC Cardiovasc Interv. 2010;3(6):660–8.

Mehta L, Devlin W, McCullough PA, O’Neill WW, Skelding KA, Stone GW, et al. Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. Am J Cardiol. 2007;99(7):906–10.

Park D-W, Kim Y-H, Yun S-C, Ahn J-M, Lee J-Y, Kim W-J, et al. Association of body mass index with major cardiovascular events and with mortality after percutaneous coronary intervention. Circ Cardiovasc Interv. 2013;6(2):146–53.

Ma W, Sun X, Wang Y, Han X, Zhu Y, Liu N. Does body mass index truly affect mortality and cardiovascular outcomes in patients after coronary revascularization with percutaneous coronary intervention or coronary artery bypass graft? A systematic review and network meta‐analysis. Obes Rev. 2018;19(9):1236–47.

Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Sisman AR, Yuksel F, et al. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin Med Res. 2010;8(2):89–95.

Beavers CJ, Heron P, Smyth SS, Bain JA, Macaulay TE. Obesity and antiplatelets-does one size fit all? Thromb Res. 2015;136(4):712–6.

Farb MG, Bigornia S, Mott M, Tanriverdi K, Morin KM, Freedman JE, et al. Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. J Am Coll Cardiol. 2011;58(3):232–7.

Neergaard-Petersen S, Hvas A-M, Kristensen SD, Grove EL. Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes. In: Seminars in thrombosis and hemostasis. Thieme Medical Publishers; 2016. p. 234–41.

Prabhakar G, Haan CK, Peterson ED, Coombs LP, Cruzzavala JL, Murray GF. The risks of moderate and extreme obesity for coronary artery bypass grafting outcomes: a study from the Society of Thoracic Surgeons’ database. Ann Thorac Surg. 2002;74(4):1125–31.

Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Obesity is not a risk factor for significant adverse outcomes after cardiac surgery. Circulation. 1996;94(9 Suppl):II87-92.

Birkmeyer NJO, Charlesworth DC, Hernandez F, Leavitt BJ, Marrin CAS, Morton JR, et al. Obesity and risk of adverse outcomes associated with coronary artery bypass surgery. Circulation. 1998;97(17):1689–94.

Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar‐Zadeh K. Effect of obesity on short‐and long‐term mortality postcoronary revascularization: a meta‐analysis. Obesity. 2008;16(2):442–50.

Wagner BD, Grunwald GK, Rumsfeld JS, Hill JO, Ho PM, Wyatt HR, et al. Relationship of body mass index with outcomes after coronary artery bypass graft surgery. Ann Thorac Surg. 2007;84(1):10–6.

Ruka E, Dagenais F, Mohammadi S, Chauvette V, Poirier P, Voisine P. Bilateral mammary artery grafting increases postoperative mediastinitis without survival benefit in obese patients. Eur J Cardio-Thoracic Surg. 2016;50(6):1188–95.

Donna K. Arnett, Roger S. Blumenthal, Michelle A. Albert, Andrew B. Buroker, Zachary D. Goldberger, Ellen J. Hahn, Cheryl Dennison Himmelfarb, Amit Khera, Donald Lloyd-Jones, J. William McEvoy, Erin D. Michos, Michael D. Miedema, Daniel Muñoz, Sidney C. Smith, Salim S. Virani, Kim A. Williams, Joseph Yeboah, Boback Ziaeian, 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, JACC, Volume 74, Issue 10, 2019, pp. e177-e232, https://doi.org/10.1016/j.jacc.2019.03.010..
DOI: 10.1016/j.jacc.2019.03.010

Juhani Knuuti, William Wijns, Antti Saraste, Davide Capodanno, Emanuele Barbato, Christian Funck-Brentano, Eva Prescott, Robert F Storey, Christi Deaton, Thomas Cuisset, Stefan Agewall, Kenneth Dickstein, Thor Edvardsen, Javier Escaned, Bernard J Gersh, Pavel Svitil, Martine Gilard, David Hasdai, Robert Hatala, Felix Mahfoud, Josep Masip, Claudio Muneretto, Marco Valgimigli, Stephan Achenbach, Jeroen J Bax, ESC Scientific Document Group, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC), European Heart Journal, Volume 41, Issue 3, 14 January 2020, Pages 407–477, https://doi.org/10.1093/eurheartj/ehz425.
DOI: 10.1093/eurheartj/ehz425

Joseph, J., Velasco, A., Hage, F.G. and Reyes, E., 2018. Guidelines in review: Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. Journal of Nuclear Cardiology, 25(2), pp.509-515.

Martin, S.S., Blaha, M.J., Blankstein, R., Agatston, A., Rivera, J.J., Virani, S.S., Ouyang, P., Jones, S.R., Blumenthal, R.S., Budoff, M.J. and Nasir, K., 2014. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation, 129(1), pp.77-86.

Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019 Sep 27;366:l5125. https://doi.org/10.1136/bmj.l5125, PMID: 31562117; PMCID: PMC6763755..
DOI: 10.1136/bmj.l5125,

Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и Дислипидемии. 2020;38(1):7-42.

Pathak RK, Mahajan R, Lau DH, Sanders P. The implications of obesity for cardiac arrhythmia mechanisms and management. Can J Cardiol. 2015;31:203-210. https://doi.org/10.1016/j.cjca.2014.10.027.
DOI: 10.1016/j.cjca.2014.10.027

Plourde B, Sarrazin JF, Nault I, Poirier P Sudden cardiac death and obesity. Expert Rev Cardiovasc Ther. 2014;12:1099-1110. https://doi.org/10.1586/14779072.2014.
DOI: 10.1586/14779072.2014

Chiuve SE, Sun Q, Sandhu RK, Tedrow U, Cook NR, Manson JE, Albert CM. Adiposity throughout adulthood and risk of sudden cardiac death in women. JACC Clin Electrophysiol. 2015;1:520-528. https://doi.org/10.1016/j.jacep.2015.07.011.
DOI: 10.1016/j.jacep.2015.07.011

Adabag S, Huxley RR, Lopez FL, Chen LY, Sotoodehnia N, Siscovick D, Deo R, Konety S, Alonso A, Folsom AR. Obesity related risk of sudden cardiac death in the Atherosclerosis Risk in Communities study. Heart. 2015;101:215-221. https://doi.org/10.1136/heartjnl-2014-306238.
DOI: 10.1136/heartjnl-2014-306238

Aune D, Schlesinger S, Norat T, Riboli E. Body mass index, abdominal fatness, and the risk of sudden cardiac death: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33:711-722. https://doi.org/10.1007/s10654-017-0353-9.
DOI: 10.1007/s10654-017-0353-9

Hookana E, Junttila MJ, Puurunen VP, Tikkanen JT, Kaikkonen KS, Kortelainen ML, Myerburg RJ, Huikuri HV. Causes of nonischemic sudden cardiac death in the current era. Heart Rhythm. 2011;8:1570-1 575. https://doi.org/10.1016/j.hrthm.2011.06.031.
DOI: 10.1016/j.hrthm.2011.06.031

Empana JP, Ducimetiere P, Charles MA, Jouven X. Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I. Circulation. 2004;110:2781-2785. https://doi.org/10.1161/01.CIR.0000146395.64065.BA.
DOI: 10.1161/01.CIR.0000146395.64065.BA

Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death: increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med. 1987;147:1725-1728. https://doi.org/10.1001/archinte.147.10.1725.
DOI: 10.1001/archinte.147.10.1725

Fraley MA, Birchem JA, Senkottaiyan N, Alpert MA. Obesity and the electrocardiogram. Obes Rev. 2005;6:275-281. https://doi.org/10.1111/j.1467-789X.2005.00199.x.
DOI: 10.1111/j.1467-789X.2005.00199.x

Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol. 2007;18:181-184. https://doi.org/10.1111/j.1540-8167.2006.00680.x.
DOI: 10.1111/j.1540-8167.2006.00680.x

Sabbag A, Goldenberg I, Moss AJ, McNitt S, Glikson M, Biton Y, Jackson L, Polonsky B, Zareba W, Kutyifa V. Predictors and risk of ventricular tachyarrhythmias or death in Black and White cardiac patients: a MADIT-CRT Trial substudy. JACC Clin Electrophysiol. 2016;2:448-455. https://doi.org/10.1016/j.jacep.2016.03.003.
DOI: 10.1016/j.jacep.2016.03.003

Lalani AP, Kanna B, John J, Ferrick KJ, Huber MS, Shapiro LE. Abnormal signal-averaged electrocardiogram (SAECG) in obesity. Obes Res. 2000;8:20-28. https://doi.org/10.1038/oby.2000.
DOI: 10.1038/oby.2000

Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70:921-924. https://doi.org/10.1016/0002-9149(92)90739-l.
DOI: 10.1016/0002-9149(92)90739-l

Duflou J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. Am Heart J. 1995;130:306-313. https://doi.org/10.1016/0002-8703(95)90445-x.
DOI: 10.1016/0002-8703(95)90445-x

Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol. 2011;57:1368-1374. https://doi.org/10.1016/j.jacc.2010.10.042.
DOI: 10.1016/j.jacc.2010.10.042

Konno T, Hayashi K, Fujino N, Oka R, Nomura A, Nagata Y, Hodatsu A, Sakata K, Furusho H, Takamura M, et al. Electrocardiographic QRS fragmentation as a marker for myocardial fibrosis in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2015;26:1081-1087. https://doi.org/10.1111/jce.12742.
DOI: 10.1111/jce.12742

Narayanan K, Zhang L, Kim C, Uy-Evanado A, Teodorescu C, Reinier K, Zheng ZJ, Gunson K, Jui J, Chugh SS. QRS fragmentation and sudden cardiac death in the obese and overweight. J Am Heart Assoc. 2015;4:e001654. https://doi.org/10.1161/JAHA.114.001654.
DOI: 10.1161/JAHA.114.001654

Brenyo A, Pietrasik G, Barsheshet A, Huang DT, Polonsky B, McNitt S, Moss AJ, Zareba W. QRS fragmentation and the risk of sudden cardiac death in MADIT II. J Cardiovasc Electrophysiol. 2012;23:1343-1348. https://doi.org/10.1111/j.1540-8167.2012.02390.x.
DOI: 10.1111/j.1540-8167.2012.02390.x

Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896-908. https://doi.org/10.1001/jama.2013.
DOI: 10.1001/jama.2013

Wu CK, Tsai HY, Su MY, Wu YF, Hwang JJ, Tseng WY, Lin JL, Lin LY. Pericardial fat is associated with ventricular tachyarrhythmia and mortality in patients with systolic heart failure. Atherosclerosis. 2015;241:607-614. https://doi.org/10.1016/j.atherosclerosis.2015.05.025.
DOI: 10.1016/j.atherosclerosis.2015.05.025

Fuller B, Garland J, Anne S, Beh R, McNevin D, Tse R. Increased epicardial fat thickness in sudden death from stable coronary artery atherosclerosis. Am J Forensic Med Pathol. 2017;38:162-166. https://doi.org/10.1097/PAF.0000000000000310.
DOI: 10.1097/PAF.0000000000000310

Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O’Donnell CJ, Fox CS, Hoffmann U. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009;30:850-856. https://doi.org/10.1093/eurheartj/ehn573.
DOI: 10.1093/eurheartj/ehn573

Shah RV, Anderson A, Ding JZ, Budoff M, Rider O, Petersen SE, Jensen MK, Koch M, Allison M, Kawel-Boehm N, et al. Pericardial, but not hepatic, fat by CT Is Associated With cv outcomes and structure: the Multi-Ethnic Study of Atherosclerosis. JACC Cardiovasc Imag. 2017;10:1016-1027. https://doi.org/10.1016/j.jcmg.2016.10.024.
DOI: 10.1016/j.jcmg.2016.10.024

Chi PC, Chang SC, Yun CH, Kuo JY, Hung CL, Hou CJ, Liu CY, Yang FS, Wu TH, Bezerra HG, et al. The associations between various ectopic visceral adiposity and body surface electrocardiographic alterations: potential differences between local and remote systemic effects. PLoS One. 2016;11:e0158300. https://doi.org/10.1371/journal.pone.0158300.
DOI: 10.1371/journal.pone.0158300

Cheng VY, Dey D, Tamarappoo B, Nakazato R, Gransar H, Miranda-Peats R, Ramesh A, Wong ND, Shaw LJ, Slomka PJ, et al. Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. JACC Cardiovasc Imaging. 2010;3:352-360. https://doi.org/10.1016/j.jcmg.2009.12.013.
DOI: 10.1016/j.jcmg.2009.12.013

Al-Mosawi AA, Nafakhi H, Hassan MB, Alareedh M, Al-Nafakh HA. ECG markers of arrythmogenic risk relationships with pericardial fat volume and BMI in patients with coronary atherosclerosis. J Electrocardiol. 2018;51:569-572. https://doi.org/10.1016/j.jelectrocard.2018.03.008.
DOI: 10.1016/j.jelectrocard.2018.03.008

Pouliopoulos J, Chik WW, Kanthan A, Sivagangabalan G, Barry MA, Fahmy PN, Midekin C, Lu J, Kizana E, Thomas SP, et al. Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. Circulation. 2013; 128:229-2308. https://doi.org/10.1161/CIRCULATIONAHA.113.002238.
DOI: 10.1161/CIRCULATIONAHA.113.002238

Arslan E, Yiginer O, Yavasoglu I et al. Effect of uncomplicated obesity on QT interval in young men. Pol Arch Med Wewn 2010; 120: 209-213.

Li W, Bai Y, Sun K et al. Patients with metabolic syndrome have prolonged corrected QT interval (QTc). Clin Cardiol 2009;32: E93-E99.

Omran J, Firwana B, Bostick В et al. Obesity Reviews. 2016 Jun; 17(6):520-30. doi: 10.1111/obr.12390. Epub 2016 Mar 8..
DOI: 10.1111/obr.12390. Epub 2016 Mar 8

Mukerji R, Petruc M, Fresen JL et al. Effect of weight loss after bariatric surgery on left ventricular mass and ventricular repolarization in normotensive morbidly obese patients. Am J Cardiol 2012; 110: 415-419.

Seyfeli E, Duru M, Kuvandik G et al. Effect of weight loss on QTc dispersion in obese subjects. Anadolu Kardiyol Derg 2006; 6: 126-129.

Isner JM, Sours HE, Paris AL, et al. Sudden,unexpected death in avid dieters using the liquid-protein-modified-fast diet. Observations in 17 patients and the role of the prolonged QT interval. Circulation. 1979;60(6):1401–1412.

Fisler JS. Cardiac effects of starvation and semistarvation diets: safety and mechanisms of action. Am J Clin Nutr. 1992;56(suppl 1):230S-234S.

Fumagalli S, Boni N, Padeletti M, Gori F, Boncinelli L, Valoti P, Baldasseroni S, Di Bari M, Masotti G, Padeletti L, et al. Determinants of thoracic electrical impedance in external electrical cardioversion of atrial fibrillation. Am J Cardiol. 2006;98:82-87. https://doi.org/10.1016/j.amjcard.2006.01.065.
DOI: 10.1016/j.amjcard.2006.01.065

Jain R, Nallamothu BK, Chan PS; for the American Heart Association National Registry of Cardiopulmonary Resuscitation (NRCPR) Investigators. Body mass index and survival after in-hospital cardiac arrest. Circ Cardiovasc Qual Outcomes. 2010;3:490-497. https://doi.org/10.1161/CIRCOUTCOMES.109.912501.
DOI: 10.1161/CIRCOUTCOMES.109.912501

Ogunnaike B.O., Whitten C.W., Minhajuddin A. et al. Body mass index and outcomes of in-hospital ventricular tachycardia and ventricular fibrillation arrest. Resuscitation, 2016;105:156-160.

Lee J., Oh J., Lim T.H. et al. Comparison of optimal point on the sternum for chest compression between obese and normal weight individuals withrespect to body mass index, using computer tomography: A retrospective study. Resuscitation, 2015, 128:1-5.

Система непрямого массажа сердца LUCASTM2. Инструкция по применению. 2011:с33

Gupta T., Kolte D., Mohananey D. et al. Relation of obesity to survival after in-hospital cardiac arrest. Am. J. Cardiol. 2016;118(5):662-667.

Shahreyar M., Dang G., Waqas B.M. et al. Outcomes of in-hospital cardiopulmonary resuscitation in morbidly obese patients. JACC Clin.Electrophysiol. 2017;3(2):174-183.

Testori C., Sterz F., Losert H. et al. Cardiac arrest survivors with moderate elevated body mass index may have a better neurological outcome: a cohort study. Resuscitation. 2011;82(7):869-873.

Makoto A., Hagiwara S., Oshimaet K. al. Obesity was associated with worse neurological outcome among Japanese patients with out-of-hospital cardiac arrest // Intens. Care Med. 2018;44:665-666.

Shahreyar M, Dang G, Waqas Bashir M, Kumar G, Hussain J, Ahmad S, Pandey B, Thakur A, Bhandari S, Thandra K, et al. Outcomes of inhospital cardiopulmonary resuscitation in morbidly obese patients. JACC Clin Electrophysiol. 2017;3:174-183. https://doi.org/10.1016/j.jacep.2016.08.011.
DOI: 10.1016/j.jacep.2016.08.011

Choy В, Hansen E, Moss A et al. Relation of Body Mass Index to Sudden Cardiac Death and the Benefit of Implantable Cardioverter–Defibrillator in Patients With Left Ventricular Dysfunction After Healing of Myocardial Infarction. Am J Cardiol 2010 Mar 1;105(5):581-6.

Samanta R et al. Influence of BMI on inducible ventricular tachycardia and mortality in patients with myocardial infarction and left ventricular dysfunction: The obesity paradox. International Journal of Cardiology. 2018; 265:148-154.

Frankel DL, Burke MC, Callans DJ. Impact of Body Mass Index on Safety and Efficacy of the Subcutaneous Implantable Cardioverter-Defibrillator. J Am Coll Cardiol EP 2018 May 4(5):652-659.

Szepietowska et al. Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events. Cardiovasc Diabetol (2016) 15:93 DOI 10.1186/s12933-016-0401-x.

Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал 2021; 26(7):4600, 128-189. https://doi.org/10.15829/1560-4071-2021-4600.
DOI: 10.15829/1560-4071-2021-4600

Wong CX, Brooks AG, Lau DH, Leong DP, Sun MT, Sullivan T, Roberts-Thomson KC, Sanders P. Factors associated with the epidemic of hospitalizations due to atrial fibrillation. Am J Cardiol. 2012;110:1496-1499. https://doi.org/10.1016/j.amjcard.2012.07.011.
DOI: 10.1016/j.amjcard.2012.07.011

Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:1501-1508. https://doi.org/10.1161/CIRCULATIONAHA.110.009035.
DOI: 10.1161/CIRCULATIONAHA.110.009035

Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154-162. https://doi.org/10.1016/S0140-6736(14)61774-8 [PubMed: 25960110].
DOI: 10.1016/S0140-6736(14)61774-8 [PubMed: 25960110]

Rosengren A, Hauptman PJ, Lappas G, Olsson L, Wilhelmsen L, Swedberg K. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J. 2009;30:1113-1120. https://doi.org/10.1093/eurheartj/ehp076.
DOI: 10.1093/eurheartj/ehp076

Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE, Buring JE, Albert CM. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation: the WHS (Women’s Health Study). J Am Coll Cardiol. 2010;55:2319-2327. https://doi.org/10.1016/j.jacc.2010.02.029 [PubMed: 20488302].
DOI: 10.1016/j.jacc.2010.02.029 [PubMed: 20488302]

Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, Twomey D, Ganesan AN, Rangnekar G, Roberts-Thomson KC, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1:139-152. https://doi.org/10.1016/j.jacep.2015.04.004.
DOI: 10.1016/j.jacep.2015.04.004

Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, Seward JB, Gersh BJ. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J. 2008;29:2227-2233. https://doi.org/10.1093/eurheartj/ehn324.
DOI: 10.1093/eurheartj/ehn324

Habib RH, Zacharias A, Schwann TA, et al. Effects of obesity and small body size on operative and long-term outcomes of coronary artery bypass surgery: a propensity-matched analysis. Ann Thorac Surg. 2005;79(6):1976-1986.

Ector J, Dragusin O, Adriaenssens B et al. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol 2007;50:234-242.

Shoemaker MB, Muhammad R, Farrell M et al. Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. Am J Cardiol 2013;111:368-373.

Sivasambu B et al. Increased Rates of Atrial Fibrillation Recurrence Following Pulmonary Vein Isolation in Overweight and Obese Patients. Cardiovasc Electrophysiol . 2018 Feb;29(2):239-245.

Glover BM et al. Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart 2018;0:1–7. https://doi.org/10.1136/heartjnl-2018-313490.
DOI: 10.1136/heartjnl-2018-313490

Van Gelder IC, Crijns HJ, Van Glist W.H. et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68:41–46.

Rashba E., Bouhouch R., Koshy S. et al. A new algorithm for transthoracic cardioversion of atrial fibrillation based on body weight. Am J Cardiol 2001;88:1043-1045.

Vostrikov V.A. Cardioversion of atrial and ventricular tachyarrhythmias. p.245-272 in book “Guide to cardiac arrhythmias”, edited E.I. Chazov, S.P. Golitsyn, GEOTAR Media, Moscow 2008. Russian (Востриков В.А. Электроимпульсная терапия предсердных и желудочковых тахиаритмий. С. 245–272 в кн.: «Руководство по нарушениям ритма сердца». Под ред. Е.И. Чазова и С.П. Голицына. М: ГЭОТАР-Медиа 2008.)

P.M. Kistler, Sanders P, Morton J. Effect of Body Mass Index on Defibrillation Thresholds for Internal Cardioversion in Patients With Atrial Fibrillation Am J Cardiol 2004 Aug 1;94(3):370-2.

Blouin R.A., Kolpek J.H., Mann H.J. Influence of obesity on drug disposition. Clin. Pharm., 1987;6(9):706‒714.

Greenblatt H.K., Greenblatt D.J. Altered drug disposition following bariatric surgery: a research challenge. Clin. Pharmacokinet. 2015;54(6):573-579.

Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, et al. Longterm effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65:2159-2169. https://doi.org/10.1016/j.jacc.2015.03.002.
DOI: 10.1016/j.jacc.2015.03.002

Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-2060. https://doi.org/10.1001/jama.2013.280521.
DOI: 10.1001/jama.2013.280521

Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222-2231. https://doi.org/10.1016/j.jacc.2014.09.028.
DOI: 10.1016/j.jacc.2014.09.028

Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, Twomey D, Gallagher C, Hendriks JML, Linz D, et al. PREVEntion and regReSsive Effect of weight- loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20:1929-1935. https://doi.org/10.1093/europace/euy117.
DOI: 10.1093/europace/euy117

Gessler N et al. Supervised Obesity Reduction Trial for AF Ablation Patients: Results from the SORT-AF trial. Europace 2021 Oct 9;23(10):1548-1558.

Voskoboinik A et al. Cardioversion of Atrial Fibrillation in Obese Patients: Results from the Cardioversion-BMI Randomized Controlled Trial. J Cardiovasc Electrophysiol. 2019 Feb;30(2):155-161.

Российский кардиологический журнал 2021;26(7):4594. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. https://doi.org/10.15829/1560-4071-2021-4594.
DOI: 10.15829/1560-4071-2021-4594

Влодзяновский В. В., Малкина Т. А., Соколов С. Ф. и соавт. Восстановление синусового ритма при персистирующей фибрилляции предсердий у больных с ожирением: новые возможности лекарственной кардиоверсии. Кардиология 2017;57(10):80–86.

Миронов Н.Ю., Влодзяновский В.В., Юричева Ю.А., и др. Проспективное рандомизированное исследование эффективности и безопасности электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 1: методология исследования и оценка эффективности. Рациональная Фармакотерапия в Кардиологии. 2018;14(5):664-9. https://doi.org/10.20996/1819-6446-2018-14-5-664-669.
DOI: 10.20996/1819-6446-2018-14-5-664-669

Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a disease: The Obesity Society 2018 position statement. Obesity (Silver Spring). 2019;27:7–9. https://doi.org/10.1002/oby.22378.
DOI: 10.1002/oby.22378

Lavie CJ, Sharma A, Alpert MA, et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis 2016; 58:393–400. https://doi.org/10.1016/j.pcad.2015.12.003.
DOI: 10.1016/j.pcad.2015.12.003

Agarwal M, et al. Relation Between Obesity and Survival in Patients Hospital-ized for Pulmonary Arterial Hypertension (from a Nationwide Inpatient Sample Database 2003 to 2011) Heart. Am J Cardiol. 2017; 120:489–493. https://doi.org/10.1016/j.amjcard.2017.04.051.
DOI: 10.1016/j.amjcard.2017.04.051

Carbone S. Obesity paradox in cardiovascular disease: where do we stand?Vasc Health Risk Manag. 2019 May 1; 15:89-100. https://doi.org/10.2147/VHRM.S168946.
DOI: 10.2147/VHRM.S168946

Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations and man-agement. Transl Res 2014; 164:345–56. https://doi.org/10.1016/j.trsl.2014.04.010.
DOI: 10.1016/j.trsl.2014.04.010

Gruson D, Ahn SA, Rosseau MF: Biomarkers of inflammation and cardiac remodeling: the quest of relevant com-panions for the risk stratification of heart failure patients is still on going. Biochem Med (Zagreb) 2011; 21:254-263. https://doi.org/10.11613/BM.2011.035.
DOI: 10.11613/BM.2011.035

Sung JK, Kim JY. Obesity and preclinical changes of cardiac geometry and function. Korean Circ J 2010; 40:5у223225–61. https://doi.org/10.4070/kcj.2010.40.2.55.
DOI: 10.4070/kcj.2010.40.2.55

Aurigemma GP, de Simone G, Fitzgibbons TP. Cardiac remodeling in obesi-ty. Circ Cardiovasc Imaging 2013; 6:142–52. https://doi.org/10.1161/CIRCIMAGING.111.964627.
DOI: 10.1161/CIRCIMAGING.111.964627

Peterson LR. Obesity and insulin resistance: effects on cardiac structure, function and substrate metabolism. Curr Hypertension Rep 2006; 8:451-6

Woodwiss AJ, Libhaber CD, Majane OH, et al. Obesity promotes left ven-tricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 2008; 21:1144–51. https://doi.org/10.1038/ajh.2008.252.
DOI: 10.1038/ajh.2008.252

Ren J, N Wu N, Wang S, R Sowers J, Zhang Y. Obesity cardiomyopathy: ev-idence, mechanisms, and therapeutic implications Physiol Rev. 2021 Oct 1;101(4):1745-1807. https://doi.org/10.1152/physrev.00030.2020.
DOI: 10.1152/physrev.00030.2020

Carbone S, Billingsley HE, Rodriguez-Miguelez P, et al. Lean mass abnormal-ities in heart failure: the role of sar-copenia, sarcopenic obesity, and cachexia. Curr Probl Cardiol 2020; 45:100417. https://doi.org/10.1016/j.cpcardiol.2019.03.006.
DOI: 10.1016/j.cpcardiol.2019.03.006

De Schutter A, Lavie CJ, Kachur S, et al. Body composition and mortality in a large cohort with preserved ejec-tion fraction: Untangling the obesity paradox. Mayo Clin Proc 2014;89:1072–9. https://doi.org/10.1016/j.mayocp.2014.04.025.
DOI: 10.1016/j.mayocp.2014.04.025

Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart fail-ure with preserved ejection fraction: a randomized clinical trial. JAMA. (2016) 315:36–46. https://doi.org/10.1001/jama.2015.17346.
DOI: 10.1001/jama.2015.17346

Ross R., Blair S.N., Arena R., et al. Importance of Assessing Cardiorespirato-ry Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Sci-entific Statement from the American Heart Association. Circulation. 2016;134: e653–e699. https://doi.org/10.1161/CIR.0000000000000461.
DOI: 10.1161/CIR.0000000000000461

Kondamudi N., Haykowsky M., Forman D.E., et al. Exercise Training for Prevention and Treatment of Heart Failure. Prog. Cardiovasc. Dis. 2017; 60:115–120. https://doi.org/10.1016/j.pcad.2017.07.001.
DOI: 10.1016/j.pcad.2017.07.001

Pandey A, Garg S, Khunger M, et al. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation 2015; 132(19):1786–94. https://doi.org/10.1161/CIRCULATIONAHA.115.015853.
DOI: 10.1161/CIRCULATIONAHA.115.015853

Pandey A, Patel M, Gao A, et al. Changes in midlife fitness predicts heart fail-ure risk at a later age independent of interval development of cardiac and non-cardiac risk factors: the Cooper Center Longitudinal Study. Am Heart J 2015;169(2): 290–7 https://doi.org/10.1016/j.ahj.2014.10.017.
DOI: 10.1016/j.ahj.2014.10.017

Liu K, Daviglus ML, Loria CM, et al. Healthy lifestyle through young adult-hood and the presence of low cardiovascular disease risk profi le in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study. Circulation 2012; 125(8):996–1004. https://doi.org/10.1161/CIRCULATIONAHA.111.060681.
DOI: 10.1161/CIRCULATIONAHA.111.060681

Zadeh A, Dijk E, Prasad A, et al. Effect of aging and physical activity on left ventricular compliance. Circulation 2004;110(13):1799-1805. https://doi.org/10.1161/01.CIR.0000142863.71285.74.
DOI: 10.1161/01.CIR.0000142863.71285.74

Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 1;347 (5):305–13. https://doi.org/10.1056/NEJMoa020245.
DOI: 10.1056/NEJMoa020245

Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. (2008) Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 156(1):13–22. https://doi.org/10.1016/j.ahj.2008.02.014.
DOI: 10.1016/j.ahj.2008.02.014

Padwal R, McAlister F, McMurray J, et al. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of indi-vidual patient data. Int J Obes (Lond) 2014; 38 (8): 1110-4. https://doi.org/10.1038/ijo.2013.203.
DOI: 10.1038/ijo.2013.203

Lavie CJ, Alpert MA, Arena R, et al. Impact of obesity and the obesity par-adox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1(2):98. https://doi.org/10.1016/j.jchf.2013.01.006.
DOI: 10.1016/j.jchf.2013.01.006

Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P., Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume M., Sohanpal S., Sanders S., Hobbs FDR. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009; 13:1–207

Oudejans I., Mosterd A., Bloemen J.A., Valk M.J., Van Velzen E., Wielders J.P., Zuithoff N.P., Rutten F.H., Hoes A.W. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 2011; 13:518–527

Weingärtner O, Hasan T, Böhm M.Pathophysiology and differential diagnosis of dyspnea Herz. 2004 Sep; 29(6):595-601. https://doi.org/10.1007/s00059-004-2594-0.
DOI: 10.1007/s00059-004-2594-0

Fries R.Differential diagnosis of leg edema. MMW Fortschr Med. 2004 Apr 15; 146(16):39-4

Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr, Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715731

Wang T, Larson M, Levy D, Benjamin E, Leip E, Wilson P, Ramachandran S. Impact of Obesity on Plasma Natriuretic Peptide Levels. Circulation. 2004;109:594–600.

Bayés-Genis A, Lloyd-Jones DM, Van Kimmenade RRJ, Lainchbury JG, Richards AM, Ordoñez-Llanos J, Santaló M, Pinto YM, Januzzi JL. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007; 167: 400–407

Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003 Jun 4;41(11):2010-7. https://doi.org/10.1016/s0735-1097(03)00405-4.
DOI: 10.1016/s0735-1097(03)00405-4

Daniels LB, Clopton P, Bhalla V. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151:999–1005

Jankowska EA , von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34:816–826.

Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Eur Heart J 2014; 35:416–418

Ewid M., Sherif H., Allihimy A.S. et al. AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Res Notes. 2020; 13: 178. https://doi.org/10.1186/s13104-020-05031-3.
DOI: 10.1186/s13104-020-05031-3

Felipe Martinez. Thyroid hormones and heart failure. Heart Failure Reviews volume 21, pages361–364(2016).

Tribouilloy C, Rusinaru D, Mahjoub H, et al. Impact of echocardiography in patients hospitalized for heart failure: a prospective observational study. Arch Cardiovasc Dis. 2008;101:465–473.

Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in heart failure: applications, utility, and new horizons. JAm Coll Cardiol. 2007; 50:381–396.

Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol. 1999; 33:164–170.

Agha SA, Kalogeropoulos AP, Shih J, et al. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail. 2009; 15: 586–592.

Hoffmann R, von Bardeleben S, ten Cate F, et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J 2005 Mar; 26(6):607-16.

Hoffmann R, Barletta G, von Bardeleben S, Vanoverschelde JL, Kasprzak J, Greis C, et al. Analysis of left ventricular volumes and function—a multicenter comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast enhanced 2D and 3D echocardiography. J Am Soc Echocardiogr 2014; 27:292-301

Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K., Parrillo J.E., Calvin J.E. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure.Am J Med 2002;112:437–445.

Hawkins N.M., Petrie M.C., Jhund P.S., ChalmersG.W., Dunn F.G., McMurray J.J.V. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130–139.

Bozkurt B, Aguilar D, Deswal A, et al; Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134: e535–e578. https://doi.org/10.1161/CIR.0000000000000450.
DOI: 10.1161/CIR.0000000000000450

Sundstrom J, Bruze G, Ottosson J, et al. Weight loss and heart failure: a na-tionwide study of gastric bypass surgery versus intensive lifestyle treatment. Cir-culation 2017; 135(17):1577–1585. https://doi.org/10.1161/CIRCULATIONAHA.116.025629.
DOI: 10.1161/CIRCULATIONAHA.116.025629

Lavie CJ, Laddu D, Arena R, et al. Reprint of: healthy weight and obesity prevention: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(Pt B):3027–3052. https://doi.org/10.1016/j.jacc.2018.10.024.
DOI: 10.1016/j.jacc.2018.10.024

Maggioni A.Р., Anand I., Gottlieb S.O. et al. Effects of Valsartan on Morbidi-ty and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme inhibitors J Am Coll Cardiol. 2002;40 (8):1414–1421

Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316 (23):1429–1435.

Effect of ramipril on mortality and morbidity of survivors of acute myocardi-al infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342 (8875):821–828.

Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338–2345.

Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril at-tenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J. 1995 Dec;16(12):1892-9. https://doi.org/10.1093/oxfordjournals.eurheartj.a060844.
DOI: 10.1093/oxfordjournals.eurheartj.a060844

McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L.,Shi V.C., Solomon S.D., Swedberg K., Zile M.R., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371: 993–1004.

Packer M., Bristow M.R., Cohn J.N. et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in pa-tients with chronic heart failure. N Engl J Med 1996; 334 (21):1349–1355.

Gattis W.A., O’Connor C.M., Leimberger J.D. et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91 (2):169–174.

Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbid-ity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.

Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients with systol-ic heart failure and mild symptoms. N Engl J Med. 2011;364 (1):11–21.

Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351 (6):543–551

McMurray J.J.V., Solomon S.D., Inzucchi S.E., et all. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. September 19, 2019. https://doi.org/10.1056/NEJMoa1911303.
DOI: 10.1056/NEJMoa1911303

Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New Engl Journal Med. 2020;383:1413-24. https://doi.org/10.1056/NEJMoa2022190.
DOI: 10.1056/NEJMoa2022190

Cleland JGF, Bunting KV, Flather MD, et all. Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range,and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35.

Solomon SD, McMurray JJV, Anand IS, et all. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-1620

Yusuf S, Pfeffer MA, Swedberg K, et all. CHARM Investigators and Com-mittees. Effects of candesartan in patients with chronic heart failure and pre-served left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-781.

Pitt B, Pfeffer MA, Assmann SF, et all. TOPCAT Investigators. Spironolac-tone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-1392.

Solomon SD, Vaduganathan M, Claggett BL, et all. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020;141:352-361.

Flather MD, Shibata MC, Coats AJ, et all. SENIORS Investigators. Ran-domized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.

Cleland JGF, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization — Heart Failure (CARE-HF) trial. Eur J Heart Fail. 2012;14:628-34. Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34:2592-9

Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547-56.

Wyse D, Friedman PL, Epstein AE. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-83

Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-8.

Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-302.

Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-5

Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.

Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874-9.

Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverterdefibrillators. N Engl J Med. 2005;353:1471-80.

Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE): a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017; 19:69–77. https://doi.org/10.1002/ejhf..
DOI: 10.1002/ejhf

Язык текста: Русский

ISSN: 2225-1685

Навигация
Аффилированные организации
Аннотация
Ключевые слова
Рубрики Mesh
Литература
Дополнительная информация

URI:4e432d48454152544a2d41525449434c452d323032322d302d332d302d362d3536

Унифицированный идентификатор ресурса для цитирования: //medj.rucml.ru/journal/4e432d48454152544a2d41525449434c452d323032322d302d332d302d362d3536/